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1 Introduction 
The term ‘Non-Hodgkin lymphoma’ (NHL) is a still widely used, but historical collective 
name for malignant diseases of the lymphoid system, including any kind of lymphoma 
except Hodgkin lymphomas. There have been different approaches to classify this group 
of heterogeneous malignancies, like the Kiel classification (Stansfeld et al., 1988), the 
Working Formulation of Non-Hodgkin’s Lymphoma for Clinical Usage (Robb-Smith, 
1982) and the current WHO classification of Malignant Lymphoma (Swerdlow et al., 
2008). The WHO classification pursues an approach in which lymphomas are 
differentiated by the cell type from which they are originating from. 
Of all malignancies listed in the annual report of the German Pediatric Cancer Registry, 
Non-Hodgkin Lymphoma (NHL) (excluding Burkitt leukemia) account for about 5-10% of 
all malignancies in children under the age of 15 in Germany (GPOH Jahresbericht, 
2013). In children and adolescents, about two thirds of all NHL belong to mature B cell 
lymphomas originating from mature B lymphocytes. Within this heterogeneous subgroup 
Burkitt lymphoma (BL), including Burkitt leukemia (B-AL), and Diffuse large B-cell 
lymphoma (DLBCL) are the most common subtypes. (GPOH Jahresbericht, 2013) 
1.1 The human Immune System 
Functionally, the immune system can be divided in two parts: the innate immune system 
and the adaptive immune system. The innate immune system comprises generic,  
non-specific functions of immune response. This includes physical and chemical 
barriers, inflammatory processes and the complement system; those are immediately 
available when a pathogen is encountered. In contrast, the adaptive immune system 
needs more time to establish. It underlies continuous modulation and is trained to 
recognize specific parts of a pathogen (antigen). Therefore, the adaptive immune 
response is stronger and more effective. Individual benefits and complex interactions 
between these two systems ensure an overall powerful immune response at any time 
point. 
Regardless of their later function, cells of the immune system derive from the same pool 
of pluripotent hematopoietic stem cells (HSC) in the bone marrow. Commitment of HSCs 
to either a myelopoietic progenitor, later differentiating into granulocytes, thrombocytes, 
monocytes or erythrocytes, or a lymphoid progenitor, giving rise to B lymphocytes, T 
lymphocytes and natural killer cells, is initiated by specific environmental signaling. 
(Murphy et al., 2008) 
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The effectors of the adaptive immune system can be further divided in cellular and 
humoral immunity-mediating components. Cellular immunity is mainly mediated by T 
lymphocytes, humoral immunity by antibodies and their producing cells, the B 
lymphocytes (Abbas et al., 2012). In mammals, B and T lymphocytes arise from the same 
lymphoid progenitor in the bone marrow (Abbas et al., 2012). Different signaling 
pathways lead the progenitor cell to migrate either to the thymus to become a T 
lymphocyte or to the generative organs (e.g. spleen, lymph nodes) to develop into a B 
lymphocyte. The latter are named after the Bursa of Fabricius, an organ in birds, which 
plays an essential role in B cell development in this species (Glick et al., 1955). 
1.2 B lymphocytes 
B lymphocytes provide their highly specific, humoral immune response by clonal 
expression of a diverse repertoire of antigen receptors, called B cell receptors (BCR). 
These BCRs are cell membrane-bound molecules which recognize and bind to specific 
antigens. If released in the blood from the lymphocytes, BCRs act independently as 
antibodies. Diversity of antigen receptors is achieved by somatic recombination, a 
process in which random compositions of genomic DNA segments of the BCR form a 
new unique antigen receptor coding sequence. The B lymphocyte maturation, starting 
from a lymphocyte progenitor in the bone marrow to a mature B cell migrating into the 
lymphoid tissue, is depended on the successful passing of certain developmental stages 
within a strictly regulated differentiation process (Figure 1). 
 HSC pro-B cell pre-B cell immature B 
cell 
mature B 
cell  
     
H-chain 
genes 
germline 
DNA 
VDJ 
rearranging 
VDJ 
rearranged 
VDJ rearranged VDJ 
rearranged 
L-chain 
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germline 
DNA 
germline 
DNA 
VJ 
rearranging 
VJ rearranged VJ 
rearranged 
Surface Ig absent absent pre-BCR IgM IgD and IgM 
Figure 1: Development of the B cell lineage 
Different stages of B cell development are depicted with corresponding status of heavy-chain (H) 
and light-chain (L) gene rearrangement. In hematopoietic stem cells (HSC) the genetic 
constitution is equal to germline DNA. During pro-B cell development, H-chain genes located on 
chromosome 14 are the first to undergo individual rearrangement of variable (V), diversity (D) and 
joining (J) segments, the so called VDJ rearrangement. This is followed by rearrangement of V 
and J segments in L-chain genes on either chromosome 2 or 22 during the pre-B cell status. 
Individually rearranged H- and L-chain genes provide the broad diversity of Immunoglobulins (Ig). 
The first Igs presented on the cellular surface during the developmental stages of immature and 
mature B cells are pentameric IgM and monomeric IgD. Modified from Murphy et al. (2008) 
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1.2.1 Commitment to the B cell lineage 
Commitment of common lymphoid progenitors to the B cell lineage depends on regular 
signaling of Interleukin 7 (IL-7) (Miller et al., 2002) in the bone marrow and expression of 
Transcription Factor 3 (TCF3) (O'Riordan and Grosschedl, 1999), Early B cell Factor 1 
(EBF1) (O'Riordan and Grosschedl, 1999) and Paired Box 5 (PAX5) (Cobaleda et al., 
2007). These transcription factors induce cell proliferation and differentiation to provide 
a large pool of progenitor cells for further maturation. At this time point, the genomic DNA 
of the progenitors is identical to the germline DNA of the individual (Figure 1) (Abbas et 
al., 2012). 
1.2.2 Somatic recombination 
The process of the somatic recombination of the BCR results in a wide repertoire of 
different antigen-recognizing lymphocytes based on a comprehensible amount of gene 
segments. On protein level BCRs show a consistent architecture, constituted of two 
identical heavy chains and two identical light chains. The amino acid sequence of every 
chain has a constant region, which determines the antigen receptors class, and a specific 
variable region, which is responsible for antigen binding. On the genomic level the chains 
are coded in the Immunoglobulin (Ig) gene loci. In human these loci are located on 
chromosome 14 for the heavy (H) chain and on chromosomes 2 and 22 for the two light 
(L) chains κ and λ,. 
The H-chain locus consists of three different clusters of genes coding for the variable 
region: starting from the 5’ end with variable (V) segments, followed by diversity (D) 
segments and ending with joining (J) segments. Further downstream, constant (C) 
segments are coding for the constant region of the receptor. The κ and λ loci show the 
same structural pattern of V and J segments, but have no D segments. V(D)J 
recombination is the process of joining different segments (called V-D-J joining), to form 
a rearranged gene, coding for the variable region. The rearrangement is catalyzed by 
lymphoid-specific endonucleases named Recombination-activating gene 1 (Rag-1) and 
Recombination-activating gene 2 (Rag-2), which are part of the V(D)J recombinases 
complex.  Furthermore, DNA repair enzymes randomly substitute, add and delete 
nucleotides at the ends of recombined segments. This process also intensifies diversity. 
Finally, the recombined ending sites are fused by ligating enzymes. (Abbas et al., 2012) 
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1.2.3 Differentiation stages of B cell maturation 
According to different recombination levels of the Ig loci and the expression of the 
respective BCRs, five developmental stages can be distinguished during B cell 
maturation. HSCs first undergo VDJ rearrangement of the H-chain locus after 
commitment to the B cell lineage and are hereinafter called progenitor B cells (pro-B). In 
the next developmental stage cells start to express the pre-antigen receptor (pre-BCR) 
requiring successful H-chain locus rearrangement. Cells expressing the pre-BCR are 
called pre B cells (pre-B). At the same time pre-B cells qualify to undergo additional 
rearrangement of one of the two L-chains. After successful rearrangement of both Ig loci 
the so called immature B cell expresses the BCR, which is membrane-bound IgM (Figure 
1). The immature B cell is able to leave the bone marrow and migrate into lymphoid 
tissues, like spleen or lymph nodes. (Abbas et al., 2012) 
Self-antigen recognizing lymphocytes represent a risk in the context of autoimmunity. To 
avoid proliferation of such cells, the affinity to self-antigens of immature B cells is 
checked in the bone marrow and peripherally in lymphoid tissue. Immature B cells 
showing a strong recognition of self-antigens are forced to undergo receptor editing, to 
remove self-reactivity. Therefore, rearrangement of the light chain locus can be repeated 
or switched to the other remaining light chain allele. Remaining self-antigen recognizing 
lymphocytes are signaled into apoptosis. Finally, expression of IgM and IgD is 
upregulated and the B cell matures to respond to antigens with proliferation and 
differentiation (Figure 1). (Abbas et al., 2012) 
1.3 Germinal center reaction 
1.3.1 Antigen-activation of B lymphocytes 
Before having actively encountered any antigens, B cells with rearranged BCR prior to 
antigen driven proliferation and further differentiation are termed ‘naïve’. Trigger 
mechanisms and sites of antigen-activation are diverse. For activation the mature B cell 
needs to physically meet the antigen directly (soluble antigens) or indirectly (by antigen-
presenting cells, e.g. macrophages, dendritic cells, B cells) (Abbas et al., 2012). Both, 
naïve and antigen-activated B cells are attracted by the chemokine CXCL13 (Legler et 
al., 1998). CXCL13 is secreted by follicular dendritic cells in follicles and recognized by 
the B cell’s CXCR5 receptor (Förster et al., 1996). After migration into the follicles, 
activated B cells establish germinal centers (GC) by proliferation (Rose et al., 1980). 
Germinal centers are subdivided in a B cell proliferative ‘dark zone’ and high level 
immunoglobulin-expressing B cell ‘light zone’ (Murphy et al., 2008). Those are 
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surrounded by resting B cells, forming the ‘mantle zone’ (Murphy et al., 2008). Within the 
germinal center reaction, antigen-activated B cells undergo the developmental 
processes of affinity maturation and class switching, which are described in the following. 
1.3.2 Affinity maturation 
Affinity maturation is a process of enhancing the antigen-binding qualities of the BCR 
and subsequently produced antibodies. The enzyme Activation-induced cytidine 
deaminase (AID) is only expressed by activated germinal center B cells 
(GCB) (Muramatsu et al., 1999). Its expression is upregulated upon CD40-ligand 
activation on the B cells surface (Fuleihan et al., 1993), which takes place in the germinal 
center reaction. AID induces random mutations in the variable region by deamination of 
cytosine bases (Abbas et al., 2012). The residue, uracil, can be substituted by any other 
base in consequence of DNA repair mechanisms. This process, called somatic 
hypermutation (SHM), originates GCBs with a diverse repertoire of slightly differing 
variable regions. GCBs with improved antigen-recognition are selected for proliferation 
and further differentiation. 
1.3.3 Class switching 
Class switching recombination (CSR) allows switching between different classes of 
expressed antibodies (e.g. IgG, IgE, IgA), each having specific effector functions. Class 
switching depends on recombination of the CH locus, in which different class-defining C 
segments are joined next to the previously formed V(D)J gene (Abbas et al., 2012). 
Again, this is achieved by cleavage of intervening DNA. AID is thought to generate 
double strand breaks in actively transcribed promoter regions (S regions) upstream of 
the primary and the designated C segment (Manis et al., 2002). This process forms DNA 
loops which locate the selected C segment next to the V(D)J region. Finally, double-
strand repair mechanisms ligate the switched regions (Murphy et al., 2008).  
After antigen-activation, affinity maturation and class switching, the GCBs differentiate 
into either antibody-producing plasma cells or resting memory cells. (Abbas et al., 2012)  
1.3.4 Malignant transformation 
The process in which a cell acquires genomic alterations that result in the phenotype of 
cancer is called malignant transformation. During the different genome-editing events in 
B cell development, lymphocytes are at risk to gain structural and punctual mutations or 
aberrations. In B lymphocytes, genomic instabilities might be fostered by either 
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accidental occasion, malfunction of DNA repair mechanisms or uncontrolled activity of 
DNA remodeling proteins like AID or Rag-1/-2. 
Lymphoid malignancies present with different characteristics according to cellular origin 
and time point of malignant transformation. For example, acute precursor B cell leukemia 
(pB-ALL) cells derive form immature progenitor cells, while BL and DLBCL derive from 
mature germinal center B cells (Figure 2). (Kuppers, 2005) 
 
Figure 2: Cellular origin of B cell malignancies 
Developmental stages of B cells are depicted starting from hematopoietic stem cells (HSC) in the 
bone marrow and ending with specialized memory or plasma cells in the blood. Progress of 
genome-editing events is shown by Ig recombination, Somatic hypermutation and Class switching 
in a timely manner. Depending on cellular origin and timepoint of malignant transformation arising 
lymphoid malignancies are listed. Precursor B-ALL, BL, B-AL and DLBCL are highlighted due to 
their role in the current study. HSC: Hematopoietic Stem Cell, GCB: Germinal Centre B cell, ACB: 
Activated B cell, B-CLL: B-cell Chronic Lymphoblastic Leukemia, DLBCL: Diffuse large B-cell 
lymphoma, PMLBL: Primary Mediastinal Large B-cell Lymphoma, Ig: Immunoglobulin. Modified 
from Kuppers (2005). 
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1.4 Mature B cell lymphoma 
1.4.1 NHL-BFM study group 
In Germany, first multicenter trials for patients with pediatric leukemia and lymphoma 
were established in the 1970s when Hansjörg Riehm (Berlin), Bernhard Kornhuber 
(Frankfurt) and Günther Schellong (Münster) founded the Berlin-Frankfurt-Münster 
(BFM) study group. Over the years more than 60 pediatric oncology departments in 
Germany joined the group. Remarkable increases in patient’s survival were achieved by 
continuous advancement of treatment approaches. In addition the validation of sufficient 
risk-stratification criteria, the reduction of acute and long-term toxicity and improved 
diagnostic criteria have been and still are essential objectives for the development of 
improved treatment strategies. (Rossig et al., 2013) 
Today, more than 95% of all pediatric patients diagnosed with mature B cell lymphoma 
in Germany are registered to the clinical trials of the NHL-BFM group (GPOH 
Jahresbericht, 2013) and treated according to standardized treatment plans. Risk-
stratification is based on the resection status, the stage of disease and the pre-treatment 
serum LDH level. Staging is assessed according to St Jude’s staging system (Murphy, 
1980). Bone marrow puncture/biopsy and lumbar puncture are obligatory to evaluate 
bone marrow and central nervous system (CNS) status. Cases with more than 25% 
blasts in the bone marrow are called Burkitt leukemia (B-AL). According to NHL-BFM 
protocols, B cell lymphoma/leukemia patients are stratified into four risk groups (R1 to 
R4). Treatment intensity is stratified according to the risk group with two to six five-day 
courses of polychemotherapy. The courses are based on dexamethasone, 
methotrexate, cyclophosphamide, ifosfamide, cytarabine, etoposid, doxorubicin, 
vincristine, vindesine and inthrathecal triple therapy. (NHL-BFM Study Group, 2012) 
1.4.2 Burkitt Lymphoma 
Burkitt lymphoma (BL) is the most common NHL subtype in pediatric patients (Burkhardt 
et al., 2005). It was first described by Denis Burkitt as a “[…] sarcoma involving the jaws 
in african children” in 1958 (Burkitt, 1958). Today, the etiology of BL is divided into an 
Epstein-Bar-Virus (EBV) related endemic group, which is mainly present in tropical 
Africa, a group related to infections with the Human immunodeficiency virus (HIV) and a 
sporadic group of cases outside of Africa. The cases investigated in this study belong to 
the latter sporadic group. In sporadic cases the median age of pediatric BL patients 
(including the diagnosis of Burkitt leukemia) at diagnosis is 8.4 years and male-female 
ratio is 4,5:1 (Burkhardt et al., 2005). 
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Typical Burkitt cells are medium-sized and show a high proliferative rate. Nucleoli 
present with clumped and dispersed chromatin, the cytoplasm is basophilic and often 
contains vacuoles. (Swerdlow et al., 2008) 
Malignant cells in pleural effusions, ascites and bone marrow typically show L3 
morphology according to the French-American-British classification (Bennett et al., 
1976). In patients with bone marrow infiltration of more than 25% Burkitt leukemia (B-
AL) is diagnosed. In this study the term BL always includes the leukemic variant, unless 
otherwise stated. 
BL cells express IgM on their surface and are usually positive for CD19, CD20, CD22, 
CD10 and BCL6. BCL2 and TdT are usually negative. (Bennett et al., 1976) 
Translocation of c-MYC to an immunoglobulin gene locus is virtually present in all cases. 
The most common translocation t(8;14)(q24;q32) localizes c-MYC under the control of 
the Ig H-chain promoter (80%), whereas translocations to the λ t(8,22)(q24;q11) or κ 
t(2;8)(p11;q24) light chain loci account for 10% of the cases each (Boxer and Dang, 
2001). As Ig loci promoters are highly activated during B cell development, c-MYC 
translocation-carrying B cells are forced to constitutive expression of c-MYC, which is 
involved in cell cycle regulation, cell growth and cellular metabolism, but also triggers 
apoptosis (Dang, 1999; Dang et al., 1999; Sanchez-Beato et al., 2003). It was shown in 
mice that c-MYC translocations alone do not necessarily result in malignant 
transformation (Nepal et al., 2008; Roschke et al., 1997). Furthermore, c-MYC 
translocations were also found in lymphocytes from healthy human individuals at a small 
number (Muller et al., 1995). This leads to the hypothesis that c-MYC positive GCBs 
require additional molecular alterations, serving as ‘second-hit’. To investigate how c-
MYC positive B cell lymphomas avoid apoptosis, oncogenes like TP53, RB1, CDKN2A, 
BAX, TP73, BCL6 and/or their pathways have been studied and were shown to be 
altered in BL at small numbers (Bhatia et al., 1992; Capello et al., 1997; Capello et al., 
2000; Cinti et al., 2000; Corn et al., 1999; Farrell et al., 1991; Gutierrez et al., 1999; 
Kalungi et al., 2011; Martinez-Delgado et al., 2002; Wilda et al., 2004; Wiman et al., 
1991). 
High initial lactate dehydrogenase (LDH) serum levels, as well as more disseminated 
disease, particularly in form of CNS positive lymphomas and bone marrow (BM) 
involvement, were shown to be poor prognostic factors (Reiter et al., 1999). However, 
currently applied combination of intensive chemotherapy regimens reach up to a total of 
90% probability of event free survival (pEFS) (Burkhardt et al., 2005; Woessmann et al., 
2005). Cases of relapse and progression remain challenging, as they often respond 
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insufficiently to therapy and present with a significantly worse prognosis (Woessmann, 
2013). 
Disruption of the ARF–MDM-2–p53 apoptotic pathway was shown for 55% of 24 pediatric 
BL cases by Wilda and colleagues (Wilda et al., 2004). Preudhomme et al. studied 48 
BL/B-AL cases for TP53 mutations, but there was no significant association with tumor 
mass or prognosis (Preudhomme et al., 1995). Nelson et al. studied a larger series of 
pediatric BL/B-AL patients registered on Children’s Cancer Group Study CCG-5961 and 
found significant inferior survival for patients with 13q deletions detected by FISH (Nelson 
et al., 2010), but no further understanding of the molecular mechanisms of these findings 
is available so far. 
1.4.3 Diffuse large B-cell lymphoma 
Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-NHL in adults (The 
Non-Hodgkin's Lymphoma Classification Project, 1997) and the second most common 
subtype in children. DLBCL presents as a more heterogeneous disease on 
morphological, molecular and immunophenotypical aspects and can therefore be divided 
into several subgroups (Swerdlow et al., 2008). However, the centroblastic (CB) variant 
is the most frequent in adults as well as in pediatric DLBCL patients. The median age at 
the time point of diagnosis in pediatric DLBCL-CB cases is 11.4 years and the male to 
female ratio 1.7:1 (Burkhardt et al., 2005).  
All DLBCL are usually positive for B cell markers CD19, CD20, CD22 and CD79a, 
whereas the expression of BCL6 varies. The cells of the most common centroblastic 
variant presents with round, medium-sized, vesicular nuclei and amphophilic to 
basophilic cytoplasma. (Swerdlow et al., 2008) 
In contrast to pediatric BL, pediatric DLBCL less often show c-MYC translocations; Rates 
are about 31-38% are reported (Deffenbacher et al., 2012; Gualco et al., 2009; Lu et al., 
2011). Gene expression profiling studies established criteria to differentiate two 
molecular signatures within DLBCL. The classification of activated B cell-like (ACB) and 
germinal-center B cell-like (GCB) subgroups is especially important in adults, where the 
latter is associated with a more favorable prognosis. (Rosenwald et al., 2002) 
In pediatric DLBCL about 75% of the cases account for the GCB subgroup (Deffenbacher 
et al., 2012; Miles et al., 2008; Oschlies et al., 2006). Compared to adults, pediatric 
patients carry IRF4 translocations (Salaverria et al., 2011) more often and the GCB 
subtype is more frequent (Klapper et al., 2012).  
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Like in pediatric BL the prognosis of DLBCL is influenced by clinical characteristics, 
including stage of disease, LDH serum levels, CNS and BM involvement status. In an 
integrated analysis of patients enrolled in the NHL-BFM trials 86,90 or 95 probability of 
event free survival (pEFS) in pediatric DLBCL was 93±2%. However, there was a strong 
impact on age and gender with respect to the outcome, as the group of adolescent girls 
had a significantly higher chance to suffer from relapse (pEFS 0.50±16%) (Burkhardt et 
al., 2011; Burkhardt et al., 2005). 
1.4.4 Unclassifiable B-NHL 
In some cases discrimination between BL and DLBCL remains unclear, due to 
ambiguous histologic features. According to the current WHO classification these cases 
are classified as “B-cell lymphoma, unclassifiable, with features intermediate between 
diffuse large B-cell lymphoma and Burkitt lymphoma” (Swerdlow et al., 2008). Most 
common is a presentation of tumors with histomorphological features of BL, but e.g. too 
low expression of proliferative markers or BCL2 positivity and partial CD10 expression 
(de Jong, 2009). These cases account for a small number in pediatric B-NHL. In this 
study the abbreviation ‘B-NHL (DD)’ is used for such cases. 
1.5 Recurrently mutated genes in B-NHL 
In a recently published study BL tumor samples of four pediatric patients diagnosed and 
treated according to the NHL-BFM protocols have been analyzed in the ICGC-MMML-
seq project (International Cancer Genome Consortium, Molecular Mechanisms in 
Malignant Lymphoma by Sequencing). Whole-genome, whole-exome and whole-
transcriptome sequencing was performed on tumor and control samples to look for 
somatic alterations that might be involved in malignant transformation and 
lymphomagenesis. The list of genes that occurred to be affected in at least two out of 
four analyzed cases included DDX3X, FBXO11, MYC, RHOA, SMARCA4, TP53 and 
ID3. (Richter et al., 2012) 
Nearly contemporaneous two further NGS studies also reported ID3 and furthermore 
TCF3 and CCND3 among their lists of candidates being recurrently mutated especially 
in BL. Furthermore, they provided evidence for functional linkage between ID3, TCF3 
and CCND3 on protein level (Love et al., 2012; Schmitz et al., 2012). Hence, these genes 
represented interesting candidates for further analysis. 
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1.6 Candidate genes ID3, TCF3 and CCND3 
The gene Inhibitor of DNA 3 (ID3) is one of four helix-loop-helix (HLH) protein coding 
genes belonging to the Inhibitor of DNA (ID) family. The ID genes lack a basic DNA 
binding site, thus preventing other HLH transcription factors from activating their target 
genes by heterodimerization (Benezra et al., 1990; Benezra et al., 1990; Murre, 2005). 
ID3 is located on the long arm of chromosome 1 and consists of three exons with a 
coding region (isoform NM_002167.4) of 360 base pairs, resulting in a protein consisting 
of 120 amino acids (NCBI Gene database, 2013). ID3 is expressed at constant levels in 
immature and mature B cells (Becker-Herman et al., 2002; Xu et al., 2007).  
During B cell maturation one important role of ID3 is the interaction with Transcription 
Factor 3 (TCF3). TCF3 is located on chromosome 19, where alternative splicing results 
in two isoforms, E12 and E47, the latter showing a higher functional activity in B cell 
specific target activation (NCBI Gene database, 2013; Sigvardsson, 2000). TCF3 
regulates numerous target genes by binding to the respective promoter sites via its HLH 
domain (reviewed in Murre (2005)). The induction of Rag enzymes for somatic 
recombination and AID for somatic hypermutation were shown to be TCF3 dependent 
(Hsu et al., 2003). Sayegh and colleagues also performed retroviral overexpression of 
ID3 in activated B lymphocytes in mice and showed reduction of AID protein levels, 
whereas ectopic TCF3 expression induced AID expression (Sayegh et al., 2003). These 
findings led to the conclusion that ID3 inhibits TCF3 dependent gene expression in B 
lymphocytes (Figure 3).  
 
 
Figure 3: ID3, TCF3, CCND3 pathway  
ID3, TCF3 and CCND3 are depicted according to their functional interplay. TCF3 is a potent 
transcription factor that activates cell-cycle regulating downstream targets like PI3K and CCND3. 
ID3 is a direct target of MYC and controls TCF3 activity by direct negative feedback regulation. 
BCR: B-cell receptor. Modified from Campo (2012) and Schmitz et al. (2012). 
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Moreover TCF3 is an important regulator of BCR signaling and stimulation of 
downstream targets in the BCR pathway (Verma-Gaur et al., 2012). Activation of the 
phosphoinositide-3-kinase (PI3K) pathway can be augmented by TCF3 overexpression 
and promotes cellular growth and survival (Schmitz et al., 2012). Furthermore, TCF3 
increases cell proliferation via direct promoter-activation of CCND3 (Cato et al., 2011; 
Schmitz et al., 2012; Song et al., 2004). CCND3 encodes for the G1/S-specific cyclin-D3 
protein and is localized on chromosome 6. Cyclin D3 is a subunit that forms activating 
complexes with cyclin dependant kinases (CDK4/6). CDK4/6 interact with the cell cycle 
inhibitors p21 and p27 (Sawai et al., 2012; Sherr and Roberts, 2004) causing inactivation 
of retino blastoma protein (Rb1) by phosphorylation. This subsequently leads to cell cycle 
progression by G1/S phase transition (Sherr and Roberts, 2004). Cato et al. 
demonstrated that cyclin D3 expression is required for proliferative expansion of GCB 
cells (Cato et al., 2011). 
Mutations in ID3, TCF3 and CCND3 
Currently there are three studies available describing mutations of the ID3 gene in BL. 
Frequency of ID3 mutations varied between 34% (Love et al.), 58% (Schmitz et al.) and 
68% (Richter et al.) in the analyzed cohorts. Schmitz et al. reported TCF3 mutations in 
11% of the cases and furthermore CCND3 mutations in 38% of the cases. CCND3 
mutations were also analyzed in the study of Richter et al., also reporting 38% of the 
cases to display these aberrations. (Love et al., 2012; Richter et al., 2012; Schmitz et al., 
2012) 
All of these studies described ID3 mutations to accumulate in the HLH domain and first 
functional analyses showed ID3 mutant proteins to be less or completely ineffective in 
inhibiting TCF3, thus forcing increased cell proliferation and survival via PI3K and 
Cyclin D3 (Love et al., 2012; Richter et al., 2012; Schmitz et al., 2012). While TCF3 
mutations also affected the bHLH domain of its isoform E47, TCF3 mutant proteins did 
not lose their function on downstream targets when compared to wildtype TCF3, but 
partially reduced ID3/TCF3 interaction and turn them immune to the inhibitory effect of 
ID3 (Schmitz et al., 2012). CCND3 mutant proteins showed an increase in cell cycle 
stimulation when compared to unaffected CCND3, thereby indicating a gain of 
function (Schmitz et al., 2012). All in all, mutations in each of the candidate genes are 
thought to contribute to cellular growth, cell survival and proliferation (Campo, 2012). 
Relevance of ID3, TCF3 and CCND3 in other malignancies 
Besides the novel finding of ID3, TCF3 and CCND3 mutations in BL by the above 
mentioned studies, no data on recurrent mutations of these candidate genes is available 
  
13 Introduction 
1
3
 
In
tro
d
u
c
tio
n
 
for other malignancies. Sequencing of ID1 was performed in 13 families with a history of 
malignant melanoma and ID3 was sequenced in a series of 94 ovarian tumors, but no 
mutations were found in either case (Arnold et al., 2001; Casula et al., 2003; Perk et al., 
2005). Another study investigated the role of genetic alterations in ID3 by sequencing of 
sorted T-cell DNA samples from 209 patients suffering from Sjögren's syndrome. The 
study was set up on the evidence of disease-associating factors in an ID3-deficient 
mouse model, but again no mutations were reported (Sellam et al., 2008). 
However, expression levels of the ID proteins have widely been investigated in a vast 
number of tumour entities, like prostate cancer (Asirvatham et al., 2007; Patel and 
Chaudhary, 2012; Sharma et al., 2012; Strong et al., 2013), lung cancer (Castanon et 
al., 2013; Kamalian et al., 2010; Kamalian et al., 2008; Li et al., 2012), medulloblastoma 
(Phi et al., 2013; Snyder et al., 2013), ovarian cancer (Arnold et al., 2001; Maw et al., 
2009) and breast cancer (Gupta et al., 2007; Mern et al., 2010; Noetzel et al., 2008; 
Wazir et al., 2013). Also clinical relevance was demonstrated in two recent studies, one 
associating high ID1/ ID3 expression levels with more advanced grade of prostate cancer 
(Sharma et al., 2012) and the other reporting correlation between ID1 and ID3 co-
expression and inferior clinical outcome in non-small cell lung cancer (Castanon et al., 
2013). Influence on cell migration was lately reported by Shuno and colleagues, who 
performed double-knockdown of ID1 and ID3 in pancreatic cancer cell lines and 
discovered decreased metastatic potential in migration assays (Shuno et al., 2010). 
Aptamer-based targeting of Id1/3 induced cell-cycle arrest and apoptosis in ovarian and 
breast cancer cells provided the basis for possible new disease modifying drugs (Mern 
et al., 2010; Mern et al., 2010), targeting this pathway. 
TFC3 is known to form fusion transcripts with PBX1 in acute lymphoblastic leukemia. 
Differences in overall survival of TCF3-PBX1-negative and –positive cases are 
discussed in controversy (Burmeister et al., 2010). Also, the role of TCF3 as a tumor 
promoter in gastric cancer was described previously (Patel and Chaudhary, 2012).  
Immunohistochemical expression of CCND3 was investigated in Hodgkin’s lymphoma 
and showed higher levels in older patients, but didn’t show any correlation with respect 
to patients outcome (Marnerides et al., 2011). 
In sum, ID proteins are functionally involved in a variety of highly aggressive tumor 
entities, with, in some studies, evidence for prognostic relevance and influence on tumor 
cell aggressiveness. In the functional context also TCF3 and CCND3 have previously 
shown to be involved in other malignancies.  
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1.7 Study objectives 
Recently published NGS studies on B-NHL noted ID3 as a recurrently altered gene in 
Burkitt Lymphoma. Also, TCF3 and CCND3 were shown to be affected at a lower 
frequency, being of special interest regarding their functions on cell cycle regulation in B 
lymphocytes and ID3 interaction. Furthermore, previous studies on ID3 gene expression 
levels support a clinical relevance in some malignancies. 
However, published data on ID3 mutations in Burkitt lymphoma showed variable 
mutation rates in the analyzed cohorts, leaving an uncertain picture on its incidence. Also 
the clinical and prognostic relevance of alterations in the three candidate genes (ID3, 
TCF3 and CCND3) is unknown. 
 
The aims of this study were 
 to analyze somatic variants in the updated set of thirteen NHL-BFM patients 
analyzed within the ICGC-MMML-seq project 
 to assess the frequency of alterations in the genes ID3, TCF3 (isoform E47, exon 
16) and CCND3 (exon 5) in a representative, uniformly diagnosed and treated 
cohort of pediatric B-NHL patients. 
 to investigate mutational patterns and distribution of mutations in the analyzed 
pathway. 
 to analyze the findings regarding clinical and prognostic relevance. 
 to investigate the occurrence of ID3 mutations in cases of pediatric pB-ALL as a 
control group of a related malignancy. 
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2 Material and methods 
In the following, the materials used in this study are summarized in separate tables for 
equipment (Table 1), kits (Table 2) and reagents (Table 3). 
2.1 Materials 
2.1.1 Equipment 
 Table 1: Equipment 
 3130xl Genetic Analyzer Applied Biosystems 
 Consort E835, Power supply 
(Electrophoresis chamber) 
Consort NV, Turnhout, Netherlands 
 DOC-PRINT HOOD - DP-CF-011.C, 
imaging and documentation system 
Vilber Lourmat Deutschland GmbH,  
Eberhardzell, Germany 
 DRI-BLOCK DB-2A Bibby Scientific Limited, Staffordshire, 
United Kingdom 
 ED Heating Immersion Circulator Julabo, Seelbach, Germany 
 Electrophoresis chamber von Keutz, Reiskirchen, Germany 
 GeneAmp PCR System 9600 Perkin Elmer, Waltham, United States 
 Hettich Mikro 220R Centrifuge Hettich AG, Bäch, Suisse 
 Incubator Memmert, Schwabach, Germany 
 Incubator shaker Braun, Melsungen, Germany 
 NanoDrop™ 1000 PEQLAB Biotechnologie GmbH, 
Erlangen, Germany 
 Navigator N28110, Scale Ohaus Corporation, Parsippany, 
United States 
 Small centrifuge, Galaxy Mini VWR, Darmstadt, Germany 
 T-Gradient Thermoblock Biometra, Göttingen, Germany 
 T-personal Combi Biometra, Göttingen, Germany 
 UV-Transilluminator Ultra Violet Products, Cambridge, 
United Kingdom 
 Video Graphic Printer UP897MD Sony Europe Limited, Surrey, United 
Kingdom 
 Vortex Mixer 7-2020 NeoLab, Mannheim, Germany 
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2.1.2 Kits 
 Table 2: Kits 
 Big Dye Terminator V 3.1 Cycle 
Sequencing Kit 
Life Technologies GmbH, Darmstadt, 
Germany  
 E.Z.N.A.® Plasmid Mini Kit I VWR International GmbH, Darmstadt, 
Germany  
 High Pure PCR Template Preparation 
Kit 
Roche Diagnostics GmbH, 
Mannheim, Germany 
 High Pure Plasmid Isolation Kit Roche Diagnostics GmbH, 
Mannheim, Germany 
 Illustra™GFX™ PCR DNA and Gel 
Band Purification Kit 
GE Healthcare, Munich, Germany 
 TOPO® TA Cloning® Kit for subcloning 
with TOP10 E. coli 
Life Technologies GmbH, Darmstadt, 
Germany 
2.1.3 Reagents and Enzymes 
 Table 3: Reagents and Enzymes 
 100% Ethanol 100% Ethanol, Riedel de Haen, 
Sigma, Seelze, Germany 
 310 and 31xx Running Buffer, 10X Life Technologies GmbH, Darmstadt, 
Germany 
 Agarose PeqGOLD Universal Agarose 
(Peqlab, Erlangen, Germany) 
 dATP Roche, Mannheim, Germany 
 dNTP Roche, Mannheim, Germany 
 Fermentas 6X DNA Loading Dye Fermentas GmbH, St. Leon-Roth, 
Germany 
 GeneRuler™ DNA Ladder Mix, ready-
to-use 
Fermentas GmbH, St. Leon-Roth, 
Germany 
 H2O LiChrosolv® Water for 
chromatography, Merck KGaA, 
Darmstadt, Germany 
 Hi-Di™ Formamide Life Technologies GmbH, Darmstadt, 
Germany 
 Isopropanol 2-Propanol, Riedel de Haen, Sigma, 
Seelze, Germany 
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 Table 3: Reagents and Enzymes 
 Lysogeny Broth (LB) media Trypton/Pepton from Casein (Roth, 
Karlsruhe, Germany) 
Bacto-Yeast-Extract (Becton 
Dickinson, Heidelberg, Germany) 
NaCl (Roth, Karlsruhe, Germany) 
 Polymerase OneTaq Polymerase 2x MM with 
Standard Buffer (New England 
BioLabs GmbH, Frankfurt am Main, 
Germany) 
 Polymerase OneTaq Polymerase 2x MM with GC-
Buffer (New England BioLabs GmbH, 
Frankfurt am Main, Germany) 
 Polymerase Taq DNA Polymerase, Recombinant 
(Invitrogen Life Technologies GmbH, 
Darmstadt, Germany) 
 Polymerase AccuPrime™ Pfx DNA Polymerase 
(Invitrogen Life Technologies GmbH, 
Darmstadt, Germany) 
 POP-7™ Polymer Life Technologies GmbH, Darmstadt, 
Germany 
 Primers (see Table 7)  
 Saltfree water  
 Sodium Acetate 3M Sodium acetate, Roth, Karlsruhe, 
Germany 
 Tris-acetate-EDTA Buffer 50x TAE Tris/Acetic Acid/EDTA Buffer 
(Bio-Rad Laboratories GmbH, Munich, 
Germany) 
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2.2 Methods 
2.2.1 Recurrent mutations in 13 pediatric BL in the ICGC-
MMML-Seq project 
Whole-genome sequencing of pediatric BL tumor and corresponding germline samples 
was performed within the ICGC-MMML-Seq project (Coordinator: Prof. M. Siebert, Kiel). 
Sequencing was performed centrally in Kiel (Prof. Dr. P. Rosenstiel). For cases of the 
NHL-BFM group, the study was approved by the Ethical Advisory Board Gießen 
(A89/11). As of June 2013 thirteen pediatric BL cases from the NHL-BFM group were 
analyzed after informed consent of patients and/or guardians (approved by the Ethical 
Advisory Board of the Faculty of Medicine in Gießen, AZ89/11).  
Whole-genome sequencing raw data were analyzed with respect to single nucleotide 
variants (SNVs) and small insertions/deletions (InDels) by Dr. M. Schlesner (DKFZ, 
Heidelberg) as previously published in Richter et al. (Richter et al., 2012). Results were 
available via the internal project database and were furthermore deposited online in the 
ICGC Data Portal (ICGC Project, 2013). 
2.2.2 Validation of ID3, TCF3 and CCND3 mutations 
The validation of candidate genes from the ICGC-MMML-Seq project for patients 
enrolled in the NHL-BFM protocols was approved by the Ethical Advisory Board of the 
Faculty of Medicine in Gießen (AZ89/11 – Amendment 06/13). 
2.2.3 Patient samples 
2.2.3.1 B-NHL samples 
The NHL-BFM group collects samples of B-NHL patients in the NHL-BFM laboratory at 
the Justus-Liebig University Gießen. The inclusion criteria in this study were as follows: 
 registered into either the trial NHL-BFM 95 or B-NHL BFM 04 after given informed 
consent 
 date of diagnosis between 01/2000 and 12/2011 
 patients diagnosed with “Burkitt lymphoma” or “Burkitt leukemia” or “Diffuse large 
B-cell lymphoma” or “B-NHL (DD)” 
 protocol patient status (no relevant treatment modifications) 
 not included in the ICGC-MMML-Seq project 
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A total of 1127 patients were eligible according to inclusion criteria. Next, the availability 
of appropriate lymphoma material in the NHL-BFM biobank was reviewed according to 
the following quality criteria: 
 availability of initial frozen tumor cells (tissue, ascites, pleural effusion or bone-
marrow only in cases of B-AL)  
 for tissue:  histological review confirming the diagnosis or cytomorphological 
review of corresponding tumor touch imprints with the diagnosis of FAB L3 blasts 
 for blasts isolated from bone marrow, ascites or pleural effusions: a 
cytomorphological review confirming at least 75% of FAB L3 blasts.  
Reports of reference histology, carried out by the trial’s reference pathologists, were 
available at the NHL-BFM study center.  
Reports of reference cytomorphology for tumor touch imprints, effusion cytospins and 
bone marrow smears were available from the NHL-BFM reference laboratory for 
Cytomorphology and Genetics, Justus-Liebig University, Gießen. 
Reports of FISH examinations were available from the Oncogenetic Laboratory in the 
Department of Pediatric Hematology and Oncology, Justus-Liebig University, Gießen or 
from other associated reference centers of the respective trial. 
Eighty-four representative cases were randomly selected. In a second step another 10 
c-MYC rearrangement positive B-NHL cases were chosen in order to enrich the cohort 
for cases with relapse. Before preparation, samples were stored at -80 °C. 
2.2.3.2 pB-ALL samples 
For the second part of this study, tumor DNA samples from 96 pediatric pB-ALL patients 
were kindly provided from the ALL-BFM study center in Kiel (Prof. Dr. M. Schrappe, Dr. 
A. Möricke). All patients fulfilled the inclusion criteria of the respective ALL-BFM trial, in 
which they have been registered including reference diagnosis and informed consent. 
2.2.4 DNA extraction from B-NHL samples 
The High Pure PCR Template Preparation Kit was used to extract high-molecular weight 
genomic DNA from tumor cells according to the protocols shown in Table 4. 
The kit is based on adsorption chromatography, which allows nucleic acids to bind to a 
glass fiber-matrix, whereas other components do not bind or can be removed by washing 
and centrifugation. 
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First, cells and extracellular matrix have to be lysed to release the nucleic acids. Proteins, 
like DNA cutting nucleases, are digested by the highly proteolytic enzyme Proteinase K. 
The suspension, containing the nucleic acids, is transferred onto a glass fiber-matrix 
provided in spin columns. Remaining cellular and extracellular components are removed 
by washing and centrifugation steps. Finally, the nucleic acids can be released from the 
glass fiber-matrix by low salt elution. 
 Table 4: DNA extraction with High Pure PCR Template Preparation Kit 
 Protocol for tumor cells, malignant effusions (pleural, ascites) and bone 
marrow 
 1. Samples were thawed at room temperature and up to 200 µl of sample 
were transfered to a sterile 1.5 ml microcentrifuge tube. 
 2. 200 µl Binding buffer and 40 µl Proteinase K solution were added. The 
solution was vortexed and immediately incubated for 10-30 minutes at 
70 °C. 
 3. After incubation 100 µl Isopropanol was added; the solution was mixed. 
 4. The solution was transferred to a Spin column which was placed into a 
sterile collection tube. 
 5. Centrifugation was carried out for 1 minute at 8000 x g. Spin column was 
transferred into a new sterile collection tube. 
 6. 500 µl Inhibitor Removal Buffer were added to the spin column. 
 7. Centrifugation was carried out for 1 minute at 8000 x g. Spin column was 
transferred into a new sterile collection tube. 
 8. First washing: 500 µl Wash Buffer were added to the spin column. 
 9. Centrifugation was carried out for 1 minute at 8000 x g. Spin column was 
transferred into a new sterile collection tube. 
 10. Second washing: 500 µl Wash Buffer were added to the spin column. 
 11. Centrifugation was carried out for 1 minute at 8000 x g. Spin column was 
transferred into a new sterile collection tube. 
 12. Drying: Centrifugation was carried out for 10 seconds at 14000 x g. Spin 
column was transferred into a sterile 1.5 ml microcentrifuge tube. 
 13. 200 µl prewarmed (70 °C) Elution Buffer were added to the spin column 
and incubated for 5 minutes. 
 14. Centrifugation was carried out for 1 minute at 8000 x g. 
 15. The eluate was stored at 4 °C until further processing. 
 Protocol for tumor tissue 
 1. Samples were thawed at room temperature and 25 mg tissue was taken 
and sliced into small pieces using a sterile scalpel. 
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 Continue Table 4 
 2. The sample, 200 µl Tissue Lysis Buffer and 40 µl Proteinase K solution 
were transferred to a sterile 1.5 ml micocentrifuge tube. The solution was 
vortexed and incubated at 55 °C overnight. 
 3. 200 µl Binding Buffer were added and incubated at 70 °C for 10 minutes.  
 4. Remaining cellular components were drawn out with a pipette tip. 
 5. Protocol for tumor cells, malignant effusions and bone marrow was 
followed, starting at step 4. 
  
2.2.5 Polymerase chain reaction 
The polymerase chain reaction (PCR) is a widely used method to amplify pieces of DNA. 
Perquisites for a PCR application are: template DNA, a thermostable DNA-Polymerase, 
2`-deoxynucleoside 5`-triphosphates (dNTPs) and two different kinds of 
oligonucleotides. These specifically bind to unique sequences in the genome thus 
defining the region to be amplified. 
To allow binding of primers DNA has to be single stranded and therefore the double 
stranded DNA is melted at 94 °C (denaturation). This step is followed by binding of the 
primers (annealing). The optimal temperature for primer binding depends on the melting 
temperature of the primer itself and the salt conditions within the approach. Therefore, 
there are different temperature conditions for each primer pair (Table 7). In a third step, 
the temperature is raised to 68 °C which is the optimum for the used DNA-polymerase 
for adding the complementary bases starting at the primer sites (extension). The steps 
of denaturation, annealing and extension are repeated several times to exponentially 
amplify the target DNA. 
The PCR reaction protocols are shown in Table 5. The PCR program is depicted in Table 
6. Primer sequences including annealing temperatures are given in Table 7.  
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 Table 5: Polymerase chain reaction 
 PCR reaction for direct sequencing 
 genomic DNA 1 µl (5 ng/µl) 
 Forward Primer 1 µl (10 pmol/µl) 
 Reverse Primer 1 µl (10 pmol/µl) 
 Polymerase* 12,5 µl 
 H2O 10,5 µl 
 Total reaction volume  25 µl 
 * OneTaq Hot Start Polymerase 2x MM with GC Buffer was used for CCND3 
amplification. Otherwise OneTaq Hot Start Polymerase 2x MM with Standard 
Buffer was used. 
 PCR reaction for subcloning 
 AccuPrime™ Pfx DNA Polymerase 1 µl 
 genomic DNA 1 µl (5 ng/ µl) 
 dNTPs 1,5 µl 
 Reaction Buffer, 10x 5 µl 
 H2O 40 µl 
 Forward Primer 0,75 µl (10 pmol/ µl) 
 Reverse Primer 0,75 µl (10 pmol/ µl) 
 Total reaction volume 50 µl 
 
 Table 6: PCR program 
 1x 10 minutes 94 °C   
 35x denaturation annealing elongation 
  45 seconds 94 °C 30 seconds, see 
Table 7 
1 minute 68 °C 
 1x 10 minutes 68 °C   
  pause at 4 °C   
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Table 7: Primer sequences   
gene primer 
name 
forward primer (5’->3’) 
reverse primer (5’->3’) 
PCR 
product 
length (bp) 
annealing 
temperature 
ID3 ID3_1* GAACCAGTGTTGGGCTAAAG 
GCAAGTCACTTGTCCCTCTC 
1034 56 °C 
ID3 ID3_2* AGGAGCTTTTGCCACTGA 
CAAAATTCGGCCATGTGCG 
1113 56 °C 
ID3 ID3_K# TCCAGGCAGGCTCTATAAGTG 
CCGAGTGAGTGGCAATTTTT 
694 56 °C 
TCF3 TCF3$ GAAATACAGGAGGCCACACG 
AGGTGTGTGAGGTGTGGATG 
609 68.5 °C 
CCND3 CCND3$ CCATGTGTTGGGAGCTGTC 
CTGGAGGCAGGGAGGTG 
328 57 °C 
* self designed, # as published in Richter et al. (Richter et al., 2012), $ as published in 
Schmitz et al. (Schmitz et al., 2012) 
 
2.2.6 Purification of PCR products 
Products of polymerase chain reaction contain residual amounts of dNTPs, primers, salts 
and genomic DNA. To obtain sufficient quality for the following sequencing reaction, 
these contaminants have been removed with the Illustra™ GFX™ PCR DNA and Gel 
Band Purification Kit. The protocol used is depicted in Table 8. 
 Table 8: Purification of PCR products using the Illustra™ GFX™ PCR DNA 
and Gel Band Purification Kit 
 Protocol for purification of PCR products from enzymatic reaction 
 1. 500 µl Capture buffer type 3 was pipetted onto a MicroSpin column, 
placed into a collection tube.  
 2. The complete PCR reaction volume was pipetted to and thoroughly mixed 
with the Caputer buffer by gently pipetting up and down. 
 3. Centrifugation was performed for 30 seconds at 16000 x g. The 
MicroSpin column was transferred into a new sterile collection tube. 
 4. 500 µl Washing buffer type 1 were added to the MicroSpin column. 
 5. Centrifugation was performed for 30 seconds at 16000 x g. The 
MicroSpin column was transferred into a new sterile collection tube. 
 6. 30 µl Eluation buffer type 6 (sterile, nuclease free water) were added. 
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 Continue Table 8 
 7. The eluate was stored at 4 °C until further processing. 
 Protocol for purification of PCR products in gel bands 
 1. The PCR reaction was subjected to agarose gel electrophoresis. DNA 
fragments were visualized using UV light and the part of agarose gel 
containing the amplificate of interest was cut out using a scalpel. 
 2. The piece of agarose was transferred into a sterile 1.5 ml microcentrifuge 
tube. 
 3. 10 µl Capture buffer type 3 were added for each 10 mg of agarose 
weight. At least 300 µl Capture buffer type 3 were added. 
 4. The solution was mixed by inversion and incubation was performed at 60 
°C for 15-30 minutes, until the agarose was completely melted.  
 5. Protocol for purification of PCR products from enzymatic reaction was 
followed, starting at step 3. 
  
2.2.7 Bacterial culture, subcloning and plasmid DNA 
preparation 
Bacterial subcloning allows the separation of a single DNA fragments. This is an 
important tool for the analysis of e.g. different alleles from a diploid organism. In the 
context of heterozygous (e.g. frameshift) mutations, analysis of sequencing results is 
convenient, as there is just one sequence read. In contrast, direct sequencing of PCR 
ampflificates may produce douple peak signals. Furthermore, after subcloning the allelic 
state can be identified in cases where more than one mutation is present in an analyzed 
sequence. 
The separation of a single DNA fragment is realized by its integration into a small piece 
of linearized double strand DNA plasmid, called vector. The ends of the linearized, here 
used TOPO TA plasmid carry 3’ thymidine overhangs. This allows the insertion of one 
DNA molecule, to which a 3’ adenine has been added previously. DNA Topoisomerase 
I conjugated to the plasmid ligates the vector and the template molecule, resulting in a 
circular double stranded plasmid. Due to its molecular structure, the plasmid is replicated 
independently when brought into a convenient host organism like Escherichia coli. 
Usually, each bacterium takes up only one plasmid and therefore, selective picking of 
plate-grown colonies allows separation of different allele representing plasmids by 
chance. 
Moreover, the plasmid contains an ampicillin resistance cassette and the lacZ gene 
encoding for beta-galactosidase enzyme. These selective markers are used during clone 
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selection: Ampicillin containing media will kill non plasmid carrying bacteria, as they are 
nonresistant to the antibiotic. Bacteria, transformed with a plasmid not containing an 
insert, will express beta-galactosidase and therefore, turn blue in the presence of 5-
bromo-4-chloro-indolyl-β-D-galactopyranoside (X-gal). As the beta-galactosidase 
encoding gene on the plasmid is disrupted by a successful insertion, these bacteria form 
white colonies and are easily selected. Bacteria are proliferated in liquid cultures and 
plasmid DNA can be extracted with spin column kits. The inserted sequence can be 
analyzed using vector specific sequencing primers (M13). 
In the current study cloning was performed using the TOPO® TA Cloning® Kit for 
subcloning with TOP10 E. coli. PCR products for cloning were generated using high 
fidelity AccuPrime™ Pfx DNA Polymerase (see PCR reaction for cloning, Table 5). To 
enrich for high quality PCR templates, reaction products were separated by gel 
electrophoresis (see Table 12). Gel band purification was performed as previously 
described in Table 8. After DNA concentration measurement, purified PCR products 
were adenylated following the protocol shown in Table 9. Cloning protocol is shown in 
Table 10 and DNA isolation from Plasmids in Table 11. Further cultivation of picked 
colonies was performed, when colony PCR (see PCR reaction for direct sequencing, 
Table 5) was positive with insert specific primers.  
 Table 9: Protocol for adenylation of PCR products 
 Reaction mixture  
 purified PCR product 8 µl 
 10x PCR Puffer (BD) 1 µl 
 dATP 0,5 µl 
 Taq DNA polymerase, Recombinant 0,5 µl 
 Protocol  
 1. Mixing of the reaction mixture 
 2. Incubation at 72 °C for 10 minutes in a thermocycler. 
 
 Table 10: Protocol for ligation and cloning 
 Protocol  
 1. Preparation of the ligation reaction mix (1 µl PCR product, 1 µl Salt 
solution, 1 µl vector, ad 6 µl H2O), incubation at room temperature for 5 
minutes 
 2. Thaw E.coli TOPO 10 cells on ice 
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 Continue Table 10 
 3. Careful addition of 2,5 µl of ligation mix to the E.coli TOP 10 cells 
 4. Incubation on ice for 10 minutes 
 5. 30 seconds heat shock at 42 °C prewarmed water bath 
 6. Set back the reaction on ice 
 7. Addition of 250 µl SOC-media 
 8. Incubation with constant shaking at 37 °C for one hour 
 9. Preparation of LB-plates (10 g Trypton/Pepton from Casein, 5 g Bacto-
Yeast-Extract, 10 g NaCl, H2O ad 1000ml, adjustment of pH 7.0, 
autoclaved) containing 50µg/ml ampicillin, greasing of 40 µl X-Gal 
 10. Prewarming of the LB-plates for 30 minutes 
 11. Greasing of 100 µl of transformed cells per plate 
 12. Incubation at 37 °C of plates overnight. 
 13. Selection of white colonies by picking 
 14. Preparation of colony PCR. 
 15. In case of successful colony PCR: inoculation of 5 ml of LB medium 
containing ampicillin (50 µg/ml), incubation at 37 °C shaking overnight, 
followed by plasmid DNA preparation according to the following protocol 
(Table 11). 
 
 Table 11: Plasmid DNA preparation with High Pure Plasmid Isolation Kit 
 Protocol  
 1. The Binding Buffer was placed on ice. 
 2. Centrifugation of 5 ml previously incubated plasmid carrying E.coli-LB 
media was performed at 6000 x g for 30 seconds. The supernatant was 
discarded. 
 3. The bacterial pellet was resuspended with 250 µl Suspension Buffer 
(RNase). Addition of 250 µl Lysis Buffer. The solution was mixed by 
inversion. 
 4. The solution was incubated at room temperature for 5 minutes. 
 5. Addition of 350µl Binding Buffer. Incubation on ice for 5 minutes. 
 6. Centrifugation was performed at 13000 x g for 10 minutes. 
 7. A High Pure Filter Tube was placed into one collection tube. The entire 
supernatant was transferred to the Filter Tube. Centrifugation was 
performed at 14000 x g for 1 minute. 
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 Continue Table 11 
 8. The Filter Tube was placed in a sterile 1.5ml microcentrifuge tube. 700µl 
Wash Buffer II were added, followed by centrifugation at 14000 x g for 
60 seconds. 
 9. The Filter Tube was transferred to a new sterile 1.5 ml microcentrifuge 
tube. 100µl Elution Buffer were added, followed by centrifugation at 
14000 x g for 60 seconds. 
 10. The eluate was stored at 4 °C until further preparation. 
 
2.2.8 Agarose gel electrophoresis 
For analysis and separation of DNA fragments agarose based gel electrophoresis was 
used. All gels were prepared using 1% Agarose (w/v) in 1xTAE buffer. For analytical 
purposes wells were loaded with previously prepared mixtures of 2 µl Loading Buffer and 
3 µl of PCR product. Electrophoresis was performed as stated in Table 12. DNA 
fragments move within the applied voltage according to their size, small fragments move 
faster than larger ones. Gels were stained in Ethidium bromide solution (10mg/l) for 15 
minutes, followed by washing in ddH2O for 10 minutes. Gels were photographed and 
analyzed on an UV-transluminator (wavelength 254 nm). 
To enrich for high quality PCR templates for subsequent cloning, the total PCR reaction 
volume of 50 µl was divided in 2x 25 µl. Each was mixed with 5 µl Loading Buffer and 
loaded to the wells of the gel. Electrophoresis and stain of gels was performed as 
described described above and in Table 12. Gels were stained in Ethidium bromide 
solution (10mg/l) for 15 minutes, followed by washing in ddH20 for 10 minutes. Bands 
were visualized using an UV-transluminator (wavelength 320 nm) and bands of correct 
size were cut from the gel using a sterile scalpel. DNA extraction from the gel bands was 
performed as described in Table 8. 
 Table 12: Protocol for agarose gel electrophoresis 
 Preparation of agarose gel solutions  
 Agarose (w/v) in 1xTAE 1% 
 Electrophoresis parameters  
 Voltage 180 V 
 Duration 45-75 minutes, depending on gel size 
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2.2.9 UV spectrometry 
After isolation of genomic DNA, purification of PCR products from PCR reactions or gel 
bands and preparation of plasmid DNA, concentration and quality of the nucleic acids 
was measured by UV spectrometry using a NanoDrop™ 1000 (PEQLAB Biotechnologie 
GmbH, Erlangen, Germany). In each case 2 µl of undiluted sample was used for the 
measurement. 
UV spectrometry allows measuring concentration and quality of nucleic acids by using a 
spectrophotometric instrument. The absorption maximum of DNA is at 260 nm and of 
RNA at 230 nm; the absorption of a test sample at these wavelengths correlates with the 
amount of these nucleic acids in the sample. The optical density (OD) of one unit 
corresponds to a concentration of 50 ng/dl of double stranded DNA (Sambrook and 
Russel, 2001). To control for protein contamination the absorption at 280 nm was 
measured. Sufficient purity for subsequent analysis was assumed if the ratio of OD260 to 
OD280 was between 1.8 and 2.0. 
2.2.10 Cycle sequencing 
Cycle sequencing is widely used to analyze the sequence of DNA templates. This 
method is based on “DNA sequencing with chain-terminating inhibtors” by Sanger et. al 
published in 1977 (Sanger et al., 1977). In comparison to a normal PCR 
dideoxynucleotides are added in addition to a taq DNA-polymerase, the 
deoxynucleotide-mix and one oligonucleotide, serving as a sequencing primer. 
First the DNA template is melted at 94 °C (denaturation) to be accessible for the 
sequencing primer to bind to the single stranded DNA (annealing). Annealing is carried 
out at 50 °C. Subsequently the temperature is raised again to the optimum of the taq 
DNA-polymerase to start synthesis along the sequencing primer site. Whenever a 
dideoxynucleotide is integrated into the new DNA strand further elongation of that 
particular DNA molecule is disrupted, because it lacks the obligatory hydroxyl group. As 
the incorporation of dideoxynucleotides and common deoxynucleotides occurs 
randomly, DNA molecules of different lengths are synthesized. Each of the four different 
dideoxynucleotides is labeled with a different dye, which can be separately detected by 
a capillary electrophoresis instrument. 
Big Dye Terminator V 3.1 Cycle Sequencing Kit was used to perform cycle sequencing 
according to the protocol shown in Table 13. Cycle sequencing was performed on a 
GeneAmp PCR System 9600 (Perkin Elmer, Waltham, USA) running the program shown 
in Table 14. Generally, each gene was sequenced in forward and reverse direction at 
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least once per patient. For validation issues either the forward or reverse primer was 
used.  
 Table 13: Cycle sequencing with Big Dye Terminator V 3.1 Cycle 
Sequencing Kit 
 Template DNA 100 ng 
 Ready Reaction Mix 2 µl 
 Sequencing Buffer (5x) 4 µl 
 Primer (Forward or Reverse) 1 µl (1 pmol/ µl) 
 H2O up to 20 µl reaction volume 
 Total reaction volume 20 µl 
 
 Table 14: Cycle sequencing program 
 1x 1 minute 96 °C   
 25x denaturation annealing elongation 
  10 seconds 96 °C 5 seconds 50 °C 4 minutes 60 °C 
  pause at 4 °C   
2.2.11 Ethanol precipitation 
To remove residual amounts of dNTPs, 2`-dideoxynucleoside 5`-triphosphates (ddNTPs) 
and primers after cycle sequencing, ethanol based precipitation was carried out. The 
protocol used is shown in Table 15. 
 Table 15: Protocol for ethanol based precipitation 
 1. The product of the sequencing reaction (volume 20 µl) is transferred 
to a sterile 1.5 ml microcentrifuge tube. 
 2. Addition of 50 µl 100% Ethanol and 2 µl sodium acetate, mixing. 
 3. Centrifugation at 4 °C for 20 minutes at 14000 x g. 
 4. Suction of the supernatant with a water-jet pump 
 5. Addition of 150 µl 70% Ethanol, mixing. 
 6. Centrifugation at 4 °C for 20 minutes at 14000 x g. 
 7. Suction of the supernatant with a water-jet pump 
 8. Drying on a heating block at 37 °C for 10-20 minutes. 
 9. Storage of the pellet at 4 °C until further processing. 
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2.2.12 Capillary electrophoresis 
Automated analysis of sequences is performed by a capillary electrophoresis instrument 
and corresponding computer software. The instrument basically consists of a capillary 
array, two buffer reservoirs and one polymer reservoir, a heating block, an optical 
detection system, a pump block and a high voltage power supply (Figure 4). A computer 
is connected via an interface to save and analyze assigned data. 
 
 
Figure 4: Charting of a capillary sequencer 
Essential components of a capillary sequencer contain an autosampler, capillary array, optical 
detection system, pump block, buffer reservoir and polymer reservoir. 
 
First the pump fills the capillary array with the polymer. In the polymer the cycle 
sequencing reaction products are separated by length, analog to the separation of DNA 
fragments in the agarose gel electrophoresis. This is followed by activation of the heating 
block to warm the polymer. Voltage is applied between the two buffer reservoirs, one 
therefore acting as anode and the other one being the cathode. The products of cycle 
sequencing reaction are injected into the capillary array. As DNA fragments are 
negatively charged, they run towards the positively charged anode. Smaller DNA 
fragments run faster so the very first fluorescently dye-labeled dideoxynucleotides 
arriving within the optical detection sytem represent the first nucleotides of the DNA 
template. The longer the fragment the later it will pass the detection system. Within the 
detection system a laser beam activates the dyes to fluoresce and the intensity is 
measured by a CCD-camera. These raw data are forwarded to a computer system which 
analyzes the digital data and visualizes those as electropherograms (Figure 5).  
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Figure 5: Method of capillary sequencing 
In the optical system a laser beam makes dye-labeled nucleotides fluorescent which are floating 
through the capillary array towards the positively charged anode. A CCD-camera device absorbs 
light-energy and forwards raw data to a computer. Analysis software allows graphic 
representation of electropherograms. 
 
A 3130xl Genetic Analyzer (Applied Biosystems) was used to perform capillary 
electrophoresis in this work. The protocol for sample preparation is shown in Table 16. 
The settings and conditions of the capillary electrophoresis instrument are shown in 
Table 17. 
 Table 16: Sample preparation for capillary electrophoresis  
 Reagents  
 Hi-Di™ Formamide  
 Protocol  
 1. Addition of 20 µl Hi-Di™ Formamide to the 1.5 ml microcentrifuge tube 
containing the dried DNA pellet after ethanol precipitation 
 2. Mix carefully, by pipetting up and down. 
 3. Transfer of the solved DNA – HiDi mixture into a designated well onto a 
96-well plate 
 4. Transfer of the 96-well plate into the capillary electrophoresis instrument 
 5. Running of the instrument according to the manual. 
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 Table 17: Capillary electrophoresis instrument settings   
 Run Module  
 Oven Temperature 60  °C 
 Poly Fill Vol 6500 steps 
 Current Stability 5.0 µA 
 PreRun Voltage 15.0 kV 
 PreRun Time 180 s 
 Injection Voltage 1.2 kV 
 Injection Time 18 s 
 Voltage Number Of Steps 30 
 Voltage Step Interval 15 s 
 Data Delay Time 120 s 
 Run Voltage 8.5 kV 
 Run Time 2780 s 
 Analysis Protocol 3130POP7_BDTv3-KB-Denovo_v5.2 
(supplied by manufacturer) 
 Software Data Collection Software 3.1.0 
 File Output Format AB1 
   
2.2.13 Analysis of electropherograms 
The software Geneious (Geneious Software, 2012) was used to load electropherograms 
and align sequences to the reference sequences (Table 18) downloaded from NCBI 
website. Previously published short nuclear polymorphisms (SNPs) were downloaded 
from dbSNP (Build ID: 137, identifiers are also listed in appendix 10.4)  (NCBI dbSNP 
database, 2013) and annotated to the reference sequences. SNPs were excluded from 
further analysis. Functional domains were annotated according to the data deposited in 
the Universal Protein Resource (UniProt database, 2013). 
 Table 18: Reference sequences 
 Gene Accession number UniProt entry 
 ID3 NM_002167.4 Q02535 
 TCF3 (Exon 16) NM_001136139.2 P15923-2 (E47) 
 CCND3 (Exon 5) NM_001760.3 P30281 
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All sequence-disagreements within the alignments were reviewed manually. To rule out 
artificial mistakes or sequencing errors, samples showing mismatches in the alignment 
were validated separately. This validation was carried out by the criteria shown in Table 
19. 
 Table 19: Validation criteria for samples showing sequence mismatches 
 Primary finding Validation requirement 
 frameshift mutation at least 1x / by cloning 
 single nucleotide substitution at least 1x 
 wildtype no validation 
   
 Cloning at least 2 out of 10 clones had to 
show the same allele disambiguates 
in sequencing  
   
 
2.2.14 Data analysis and interpretation of sequencing results 
Disambiguate results confirmed within a validation experiment were considered to be 
genomic variants. Variants were described using the reference sequence of the 
corresponding coding DNA available from the NCBI database. Potential change on 
protein level was determined by translation using a RNA codon table. The nomenclature 
provided by the Human Genome Variety Society (den Dunnen and Antonarakis, 2000) 
(Version 2.0) was applied. 
2.2.15 Definition and terminology of mutations 
In this study the term ‘mutation’ was used when the genomic variant predicted an amino 
acid change on protein level. For description of silent changes or changes that occurred 
in introns, the term ‘genomic variant’ was used. 
Mutations were termed heterozygous or homozygous with respect to presentation of 
peak heights in electropherogram analysis: disambiguates with clearly prominent non-
reference peaks were described as ‘homozygous’. However, combination of focal loss 
of one ID3 allele and occurrence of mutation on the remaining allele must be taken into 
account in such cases. Regarding the relevance on protein level homozygous presenting 
cases were considered to feature ‘biallelic involvement’. In the following, five examples 
of certain mutation types are shown. 
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Example 1 (case 83):  
The ID3 sequence cutout (Figure 6) 
shows a nucleotide change from cytosine 
to thymine that occurred at position 
c.190. In the middle of the sequence a 
double peak is visible. The height of the 
cytosine peak (blue) almost equals the 
height of the alternate thymine peak 
(green). This change was considered to 
be a heterozygous substitution.  
Result: c.190C>T 
 
 
Figure 6: Example 1 – Heterozygous 
substitution in case 83. 
Example 2 (case 55): Figure 7 depicts a 
sequence cutout with a change at 
position c.144 resulting in a nucleotide 
substitution from cytosine to guanine. 
The cytosine reference peak (blue) was 
considerably lower compared to the 
alternate guanine peak (yellow). This 
change was rated to be a homozygous 
substitution.  
Result: c.[144C>G][(144C>G)] 
 
 
Figure 7: Example 2 – Homozygous 
substitution in case 55. 
 
Example 3 (case 15): ID3 forward 
(above) and reverse (below) sequences 
are shown as an excerpt (Figure 8) with 
double peaks starting at position c.120. 
Double peaks appeared continuous until 
the end of sequence. Manual read out of 
the alternative sequence detected a 
guanine deletion at position c.120, with 
subsequent shift of the reading frame. 
This change was rated heterozygous, 
due to a peak-to-peak ratio of averagely 
1:1. 
Result: c.120delG  
Figure 8: Example 3 – Heterozygous deletion 
in case 15. 
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Example 4 (case 91): The ID3 sequence 
cutout (Figure 9) presents with a yellow 
(guanine) extra peak at position c.94, 
which is not matching with the reference 
sequence (not shown). As the previous 
peak is also reporting for a guanine 
nucleotide at this position, this change is 
a single nucleotide duplication of position 
c.93. As shown by the clear ongoing 
sequence, this change seemed to affect 
both alleles and was therefore rated to be 
homozygous. 
Results: c.93dupG 
 
 
Figure 9: Example 4 – Homozygous 
duplication in case 91. 
Example 5 (case 81): Three different sequence cutouts are shown in Figure 10. In the 
upper line the forward sequence from direct sequencing is shown, presenting with four 
double peaks that indicate heterozygous single nucleotide substitutions (red arrows). 
The middle line presents sequence obtained after cloning (clone number 8), showing 
that mutations c.[190C>G;206T>C;229A>G] occurred on the same allele. In the third 
sequence (clone number 9), c.166C>G is present, but not the previous mentioned 
mutations. In conclusion, the mutations affected different alleles. 
Result: c.[166C>G];[190C>G;206T>C;229A>G] 
 
 
Figure 10: Example 5 – Multiple substitutions and biallelic involvement in case 81. 
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2.2.16 Statistical analysis 
Statistical analysis was performed in order to identify differences in patient 
characteristics, such as gender, age, stage of disease, BM involvement, CNS 
involvement, LDH levels, diagnosis, probability of event free survival (pEFS) and overall 
survival (pOS) according to the mutation status of the analyzed candidate genes. Clinical 
data for each calculation referred to patients with successful investigation of the 
respective criteria. 
Fisher’s exact test (Fisher, 1922) was used to calculate probabilities (p values) in 2x2 
contingency tables when less than 10 patients were analyzed in this specific setting. In 
2x3, 2x4 and 2x2 tables with total counts of at least 10, Pearson's chi-squared test 
(Pearson, 1900) was applied. 
pEFS was calculated according to Kaplan and Meier (Kaplan and Meier, 1958) under 
consideration of the time between date of diagnosis and either date of event or date of 
last follow-up. Patients with a follow-up less than two years were excluded from analysis. 
Differences in pEFS were compared by the log-rank test (Mantel, 1966). 
Significant differences were assumed when the respective p value was lower than 0.05. 
Chi-square tests, pEFS and overall survival were calculated by Dr. Martin Zimmermann, 
statistician of the NHL-BFM group (Pediatric Hematology and Oncology, Hanover 
Medical School (MHH), Germany). Calculations were conducted using SAS statistical 
program (SAS-PC, Version 9.3, Cary, NC: SAS Institute Inc.) 
Fisher’s exact tests and corresponding graphics were calculated using the software 
Prism 6 for Mac OS X (Version 6.0c Trial), GraphPad Software, San Diego California 
USA. The two-tailed option was used. 
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3 Results 
3.1 Recurrent mutations in 13 pediatric BL in the 
ICGC-MMML-Seq project 
Malignant mechanisms in mature aggressive B cell Non-Hodgkin lymphoma are under 
investigation in the ICGC-MMML-Seq project. As of June 2013, thirteen pediatric BL 
cases of the NHL-BFM study have been analyzed by whole-genome and whole-
transcriptome sequencing. Datasets on single nuclear variants (SNVs) and small InDels 
were available by the projects database platform and are furthermore published online 
in the ICGC Data Portal (ICGC Project, 2013). 
Within the 13 pediatric BL cases a total of 35,208 somatic SNVs were detected. The 
mean of somatic SNVs per case was 2,708 (range 1,635-4,923) and the median of 
potentially protein changing mutations was 28 (range 11 to 46). The distribution of SNVs 
is summarized in Table 20. 
 
 Table 20: Overview of SNV counts from 13 pediatric BL cases analyzed in 
the ICGC-MMML-Seq project 
  total of SNVs range number per patient 
 all SNVs 35,208 1,635-4,923 
 exonic  447 14-56 
  silent 103 3-13 
  non-silent 344 11-46 
 non-exonic  34,761 1,599-4,867 
 
The list of genes that were affected by exonic, non-silent mutations (either SNVs or small 
InDels) included 374 different genes. Table 21 presents recurrently affected genes that 
were altered in more than three of the thirteen cases at a time.  
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 Table 21:  Recurrently mutated genes in > 3 pediatric BL cases analyzed 
in the ICGC-MMML-Seq project 
 gene #/13 function mutations typically 
found in 
 MYC 10 cell cycle progression, 
apoptosis and cellular 
transformation 
Burkitt lymphoma 
 TP53 9 tumor suppressor protein various malignancies 
 CCND3 7 regulation of CDK kinases  
 FBXO11 6 adapter protein to p53  
 SMARCA4 6 SNF/SWI chromatin 
remodeling complex 
Medulloblastoma 
 ID3 5 inhibition of HLH proteins  
 RHOA 5 cell cycle regulation  
 DDX3X 4 cellular growth and division Medulloblastoma 
 P2RY8 4 G protein coupled receptor DLBCL, translocations in 
ALL 
 
Regarding the pathway of interest in the current study, ten out of 13 cases showed 
alterations in either ID3, CCND3 and/or TCF3 (Table 22). 
 
 Table 22:  ID3, TCF3 and CCND3 mutations in 13 pediatric BL cases 
analyzed in the ICGC-MMML-Seq project 
 ID in the ICGC database ID3 TCF3 CCND3 
 4190495 x x  
 4194218 x  x 
 4194891 x  x 
 4189998 x  x 
 4182393 x   
 4193278  x  
 4177856   x 
 4142267   x 
 4125240   x 
 4177434   x 
 4112512    
 4119027    
 4133511    
 x: Mutation in the gene indicated 
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3.2 Validation of ID3, TCF3 and CCND3 mutations in 
pediatric B-NHL 
3.2.1 Characterization of analyzed samples 
3.2.1.1 B-NHL samples of the study cohort 
Eighty-four patients were selected for tumor DNA preparation according to the inclusion 
criteria of the study (see Patients samples). Tumor cell origin of the analyzed samples is 
shown in Table 23. This set of analyzed cases is referred to as ‘study cohort’.  
 Table 23: Origin of tumor cell samples in the study cohort 
 frozen tumor tissue 60 
 frozen cells from bone-marrow aspirates (buffy 
coats) 
10 
 frozen cells from malignant pleural effusions 8 
 frozen cells from malignant ascites 6 
 total 84 
  
For each type of tumor cell origin one representative micrograph is shown in example 
indicating the typical appearance of the predominance of malignant cells: tumor tissue 
imprint (Figure 11), bone-marrow aspirate (Figure 12), pleural effusion (Figure 13) and 
malignant ascites (Figure 14). As usual for hematologic evaluation smears were stained 
with a common staining according to Pappenheim. 
 
Figure 11: Example for a tumor imprint 
Medium-sized cells (red arrow) represent 
blasts. A minor fraction of cells mostly 
represents lymphocytes (case 77, BL, 
Pappenheim staining, 60x magnification). 
 
Figure 12: Example for Bone marrow aspirate 
(smear) 
Almost only medium-sized blasts are 
represented (red arrow). Also few 
erythrocytes can be seen (case 14, B-AL, 
Pappenheim staining, 60x magnification) 
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Figure 13: Example for pleural effusion 
(cytospin) 
Almost only medium-sized blasts are 
represented (red arrow). Few smaller 
lymphocytes can be seen (case 88, BL, 
Pappenheim staining, 60x magnification) 
 
Figure 14: Example for ascites (cytospin) 
Most cells represent medium-sized blasts 
(red-arrow). Also few lymphocytes and 
erythrocytes can be differentiated (case 31, 
DLBCL, Pappenheim staining, 60x 
magnification) 
 
3.2.1.2 B-NHL samples of patients who relapsed 
In a second step the study cohort was expanded to disproportionally enrich for patients 
who suffered from relapse. Importantly the initial material of these cases was analyzed; 
not the samples at the diagnosis of relapse. These cases are referred to as ‘extended 
cohort’. Tumor cell origin of the selected samples is summarized in Table 24. 
 Table 24: Origin of tumor cell samples in the extended cohort 
 frozen tumor tissue 6 
 frozen cells from bone-marrow aspirates (buffy 
coats) 
2 
 frozen cells from malignant pleural effusions 1 
 frozen cells from malignant ascites 1 
 total 10 
 
3.2.1.3 Acute lymphoblastic leukemia samples 
To compare the results obtained on the study cohort, a total of 96 tumor DNA samples 
from pediatric precursor B-cell acute lymphoblastic leukemia (pB-ALL) patients was also 
analyzed for ID3 mutations. pB-ALL samples were kindly provided from the ALL-BFM 
study group (Prof. Schrappe, Kiel). Tumor DNA was derived from either initial bone 
marrow aspirates or peripheral blood after review of blast count by the ALL-BFM study 
center. 
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3.2.1.4 Patient characteristics of the study cohort 
Between January 2000 and December 2012, 1127 eligible patients were registered in 
the NHL-BFM data center. The patient characteristics from 84 analyzed patients and 
1043 not analyzed patients are presented in Table 25. The groups of analyzed and not 
analyzed patients were similar regarding gender, age, bone marrow (BM) involvement, 
central nervous system (CNS) involvement, stage of disease, LDH levels, histological B-
NHL subtype and outcome (Figure 15, Figure 16). Therefore, the studied cohort featured 
representative characteristics for pediatric B-NHL patients in the NHL-BFM trials. 
 
 
Figure 15: Event-free survival of analyzed and 
not analyzed patients. 
 
 
Figure 16: Overall survival of analyzed and not 
analyzed patients. 
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Data refer to patients with successful investigation of the respective criteria. n: number, y: years, 
p value: probability value, BM: bone marrow, CNS: central nervous system, LDH: lactate 
dehydrogenase, U/l: Units per liter, pEFS: probability of event-free survival, pOS: probability of 
overall survival, LR: log-rank 
 Table 25: Patient characteristics of study cohort 
 Characteristics Patients not 
analyzed (n=1043) 
Patients 
analyzed (n=84) 
p value 
 Gender male 827 80% 69 82%  
  female 216 20% 15 18% 0.53 
 Age < 10 y 525 50% 43 51%  
  10-14 y 349 34% 27 32%  
  > 14 y 169 16% 14 17% 0.97 
 Stage of disease stage I 98 10% 5 6%  
  stage II 250 25% 14 18%  
  stage III 420 42% 43 55%  
  stage IV 75 8% 3 4%  
  B-AL 163 15% 14 18% 0.17 
 BM involvement yes 199 19% 14 17% 0.59 
 CNS 
involvement 
yes 101 10% 8 10% 0.96 
 LDH < 500 U/l 608 59% 39 46%  
  500-1000 U/l 156 15% 16 19%  
  > 1000 U/l 264 26% 29 35% 0.07 
 Diagnosis BL 581 56% 49 58%  
  B-AL 163 16% 14 17%  
  DLBCL 267 25% 16 19%  
  B-NHL DD 32 3% 5 6% 0.23 
 Outcome pEFS (2y) 90 ± 1%  89 ± 3%  0.84 
(LR) 
  pOS (2y) 93 ± 1%  91 ± 3% 0.82 
(LR) 
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3.2.2 ID3, TCF3 and CCND3 sequencing in B-NHL 
3.2.2.1 Results of ID3 sequencing 
ID3 mutation status was analyzed in the validation cohort by sequencing of the full ID3 
coding region. ID3 mutations were found and verified in 56/84 B-NHL samples. The 
spatial distribution of ID3 mutations is depicted in Figure 18. A detailed description of the 
genomic variants including the predicted change on protein level is presented in 
appendix 10.1.  
Frequency of ID3 mutations according to diagnosis 
ID3 mutation frequency according to diagnosis was 73% for BL, 93% for B-AL and 25% 
for DLBCL. In the subgroup of five analyzed cases with the diagnosis B-NHL (DD) three 
cases showed mutations in ID3. Table 26 reports the absolute counts of cases with 
(ID3mut) and without (ID3wt) mutations according to the histological diagnosis. ID3 
mutations occurred at a higher frequency in BL/B-AL cases when compared to DLBCL 
(Figure 17). 
 Table 26: ID3 mutations according to diagnosis 
 Diagnosis total ID3wt ID3mut ID3mut % 
 BL 49 13 36 73% 
 B-AL 14 1 13 93% 
 DLBCL 16 12 4 25% 
 B-NHL (DD) 5 2 3 60% 
 
 
Figure 17: Correlation of ID3wt and ID3mut cases according to diagnosis. 
ID3mut cases occurred at a higher frequency in BL/B-AL when compared to DLBCL. 
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Figure 18: ID3 mutations in the study cohort. 
The ID3 coding region of exon 1 is illustrated with single base pair substitutions on the upper and more complex alterations (insertions, deletions, InDels, 
duplications) on the lower site. Substitutions resulting in a nonsense mutation are depicted in red. Hatched bars delineate deletions and InDels, dotted 
bars characterize insertions and duplications. Each mutation is labeled with correspondent description on genomic and protein level, as well as the 
absolute number of occurrence in brackets. The functional helix-loop-helix domain is mapped according to UniProt entry Q02535 (UniProt database, 
2013).
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Number and type of ID3 mutations 
Of the 56 B-NHL cases with ID3 mutations, 31 cases presented with multiple mutations 
in ID3: 
 26 cases with two ID3 mutations 
 4 with three ID3 mutations 
 one with four ID3 mutations 
In the remaining 25 cases, one ID3 mutation each was detected. 
Figure 19 depicts the distribution of ID3 mutations in the 56 B-NHL cases with identified 
alterations. 
 
Figure 19: Distribution of the number of ID3 mutations in 56 B-NHL cases 
 
Ninety-three ID3 mutations were found in the 56 B-NHL cases, including 66 substitutions, 
17 deletions, 4 duplications, 3 insertions and 3 InDels (deletion followed by an insertion) 
(Figure 20).  
 
Figure 20: Mutation types found in 56 B-NHL cases 
 
Five mutations presented with homozygous characteristics in sequence analysis: three 
substitutions and two deletions. 
Four disambiguates were genomic variants that were not predicted to result in change 
on amino acid level: c.144C>T, c.193A>T, c.300+44T>C and c.301-23C>T. However, all 
these cases also harbored at least one other ID3 mutation. 
Concerning the 66 substitutions, mutations affected the nucleotide base pairs G/C in 
74% (49/66) and A/T in 27% (18/66) of the cases. The substitutions occurred in the 
genomic region between c.135 and c.300+1, which contains a G/C-content of 64%. 
Assuming a random chance for mutations to affect nucleotides in this selected region, a 
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distribution of 44 hits in G/C base pairs and 25 in A/T base pairs would have been 
expected. There was no significant difference between these expected values and the 
findings, indicating no certain preference of the underlying mutation mechanism on 
affecting G/C or A/T base pairs. 
Biallelic involvement and homozygous mutations 
To investigate whether mutations occurred on the same or different alleles, ten out of 31 
cases with the finding of multiple mutations in ID3 where selected for cloning. Sequence 
analysis of different clones from the same sample showed different alleles to be affected 
in all analyzed cases (Table 27).  
In the group of five homozygous mutations two were also analyzed by cloning. In both 
cases, the mutation was present in at least 80% of the clones, supporting evidence of 
biallelic involvement. This finding could indicate either a mutation affecting both alleles 
or combined focal ID3 loss and occurrence of a mutation on the remaining allele. 
However, in either case this would functionally result in expression of only altered or 
impaired ID3 protein and therefore this effect was considered as biallelic involvement 
with respect to the effect on protein level.  
Table 27 summarizes sequencing results of the 10 heterozygous and 2 homozygous 
cloned cases, whose DNA has been subcloned. 
 Table 27: Results of ID3 clone sequencing of selected cases 
 case allele 1 (number of clones) allele 2 (number of clones) effect 
 35 c.[167C>T] (3) c.[181_209del]  (2) biallelic 
 11 c.[144C>G] (6) c.[300+1G>C] (4) biallelic 
 23 c.[236_251delinsC] (3) c.[300+1G>C] (4) biallelic 
 73 c.[81delC] (2) c.[247_248ins] (6) biallelic 
 80 c.[160C>G] (2) c.[165_166insG] (2) biallelic 
 1 c.[198_199insCTAAG] (3) c.[194G>A] (4) biallelic 
 81 c.[166C>G] (5) c.[190C>G;206T>C;229A>G]  
(2) 
biallelic 
 8 c.[144C>G;243G>C] (5) c.[236_243del] (4) biallelic 
 10 c.[153_164del] (3) c.[256_266del] (4) biallelic 
 53 c.[134_140dup]  (5) c.[209T>C] (2) biallelic 
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 Continue Table 27 
 case allele 1 (number of clones) allele 2 (number of clones) effect 
 54 c.[214_243del] (9) wildtype (1) biallelic 
 92 c.[122_130del] (5) wildtype (0) biallelic 
 
Focal ID3 loss in cases with homozygous ID3 mutation 
In order to investigate the likelihood of focal ID3 loss in cases that presented with 
homozygous characteristics in electropherogram analysis, the occurrence of genomic 
variants at SNP positions was assessed for all cases analyzed in the study cohort and 
the extended cohort. This analysis was based on the assumption that cases with 
heterozygous SNPs are less likely presenting allelic loss, while cases with only 
homozygous SNPs in ID3 could represent focal loss of one allele. SNPs within the ID3 
coding region that were investigated for this analysis are listed in appendix 10.4. 
In total, 56 cases showed at least one heterozygous SNP and 38 cases showed only 
homozygous SNPs. Interestingly, none of the cases with apparent homozygous ID3 
mutation presented with a heterozygous SNP simultaneously. Frequency of cases 
without any heterozygous SNPs was remarkably higher in cases without homozygous 
ID3 mutation (Table 28).  
 Table 28: Correlation of cases with heterozygous SNPs and ID3 mutations 
presenting homozygous 
 Heterozygous 
SNP 
total all other cases of 
study cohort and 
extended cohort 
homozygous 
ID3mut  
p value 
(Fisher) 
 
 yes 56 56 0  
 no 38 31 7  
 total 94 87 7 0.0012 
 
Mutational hotspots 
The dataset of ID3 mutations in the study cohort showed a number of recurrent changes 
affecting the same nucleotide position. For this analysis also deletions, insertions, 
duplications and InDels have been taken into account by counting the first nucleotide 
affected, respectively. 
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Changes of c.C190 were most often (13), followed by c.C166 (10) and c.C241 (5). Table 
29 gives an overview on genomic ID3 nucleotide positions that occurred to be affected 
in more than two cases.  
 Table 29: ID3 hotspot mutations (nucleotide positions affected in > 2 
cases) 
 nucleotide and position number of cases affected 
 c.C190 13 
 c.C166 10 
 c.C241 5 
 c.C167 4 
 c.C144 3 
 c.T209 3 
 c.A236 3 
 c.G300+1 3 
 
Mutations affecting the functional ID3 Helix-Loop-Helix domain 
The helix-loop-helix (HLH) domain of ID3 is the proteins functional site of interaction with 
other HLH proteins. On the genomic level 77 of 93 (83%) mutations directly occurred 
within the HLH coding region. The remaining 18 mutations were allocated either close to 
the splice-site of exon 1 (4 cases), upstream (8 cases) or downstream (5 cases) of the 
HLH domain or in the intronic region between exon 1 and 2 (1 case). Of notice, all cases 
with a mutation not directly affecting the HLH domain or the splice-site had at least a 
second mutation in the HLH domain (Figure 18). 
3.2.2.2 Results of TCF3 sequencing 
The coding region of exon 16 nearly covers the full HLH domain coding sequence. 
Furthermore it was shown by the index studies that mutations in TCF3 always occurred 
in this exon. Therefore, exon 16 was analyzed for TCF3 mutations in the study cohort. 
TCF3 mutations were identified in eight out of 84 cases. All changes were heterozygous 
substitutions and there was no case presenting multiple mutations in TCF3.  
Figure 21 shows the distribution of mutations in TCF3 exon 16. The detailed description 
of genomic variants including the predicted change on protein level is presented in 
appendix 10.1.  
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Figure 21: TCF3 mutations in the study cohort 
The coding region of TCF3 exon 16 is illustrated. Each substitution is labeled with correspondent 
description on genomic and protein level, as well as the absolute frequency of occurrence in 
brackets. The functional basic-Helix-Loop-Helix domain is mapped according to the description 
of the functional sites in UniProt entry P15923-2 (UniProt database, 2013). 
 
Frequency of TCF3 mutations according to diagnosis 
The overall finding of mutations in TCF3 was considerably lower compared to the high 
frequency of ID3 mutated cases. In BL/B-AL the frequency of TCF3 mutations was 13% 
(8/63). There were no mutations of the TCF3 gene in cases with the diagnosis of DLBCL 
or B-NHL (DD). Absolute counts of cases with (TCF3mut) and without (TCF3wt) mutations 
in TCF3 are presented in Table 30. 
 Table 30: TCF3 mutations according to diagnosis 
 Diagnosis total TCF3wt TCF3mut TCF3mut % 
 BL 49 43 6 12% 
 B-AL 14 12 2 14% 
 DLBCL 16 16 0 0% 
 B-NHL (DD) 5 5 0 0% 
 
Number and types of mutation, mutation hotspots 
Due to the small number of TCF3 mutations, it was not possible to gain informative 
results regarding different types of mutation and recurrently affected nucleotides. One 
mutation, G1675A, was present in two cases. 
Mutations affected the TCF3 bHLH domain in all cases 
All eight mutations occurred in or in between the coding region of the bHLH binding 
domain of TCF3 (Figure 21).  
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3.2.2.3 Results of CCND3 sequencing 
CCND3 exon 5 was sequenced to analyze for CCND3 mutations in the study cohort.  
Exon 5 was previously shown to represent a mutation hotspot in BL by the index studies. 
CCND3 mutations were present in 26/84 (31%) cases. The findings are depicted in  
Figure 22. The complete description of genomic variants including the predicted change 
on protein level is presented in appendix 10.1. 
 
Figure 22: CCND3 mutations in the study cohort. 
The coding region of CCND3 exon 5 is illustrated, with substitutions on the upper and more 
complex alterations (insertions, deletions, indels, duplications) on the lower site. Substitutions 
resulting in a nonsense mutation are depicted in red. Hatched bars delineate deletions and indels, 
dotted bars characterize insertions and duplications. Each mutation is labeled with correspondent 
description on genomic and protein level, as well as the absolute frequency of occurrence in 
brackets. A part of a functional helix domain is mapped according to the description of the 
functional sites in UniProt entry P30281. 
 
Frequency of CCND3 mutations according to diagnosis 
In the study cohort, 26 cases harbored CCND3 mutations. Twenty-three out of 63 BL/B-
AL cases (37%) presented with a mutation in CCND3. In DLBCL there were two out of 
16 cases affected. One mutation was present in a case with B-NHL (DD) diagnosis. 
Table 31 summarizes absolute counts of CCND3 mutations according to diagnosis. 
 Table 31: CCND3 mutations according to diagnosis 
 Diagnosis total CCND3wt CCND3mut CCND3mut % 
 BL 49 34 15 31% 
 B-AL 14 6 8 57% 
 DLBCL 16 14 2 13% 
 B-NHL (DD) 5 4 1 20% 
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Number and types of mutation 
In the analysis of the CCND3 gene, only heterozygous mutations were detected and no 
cases presenting with more than one mutation. 
The 26 cases with CCND3 mutation included 5 deletions, 11 duplications and 10 single 
nucleotide substitutions (Figure 23). 
Figure 23: CCND3 Mutation types found in 26 B-NHL cases 
 
Mutation hotspots 
Mutations affected nucleotide c.C811 with a cytosine duplication in 9 cases, resulting in 
a protein elongating frameshift. Four cases presented with c.T869G substitution and 
three cases had c.C580T mutation. 
3.2.2.4 Mutual relationship of mutations in different candidate genes and 
correlation with MYC rearrangement 
ID3, TCF3 and CCND3 sequencing results were integrated to analyze mutual 
relationship. The majority of cases with mutations had an exclusive mutation of ID3 
(51%). The combination of ID3mut and CCND3mut was present in 31% of the cases. There 
were two cases (case 12, case 33) that had mutations in all three genes. 
Table 32 and Figure 24 summarize and present different combinations of simultaneous 
occurrence of ID3, TCF3 and CCND3 mutations in non-wildtype cases. Table 34 gives 
an overview on mutual relationship of overall sequencing results including diagnosis and 
MYC rearrangement. 
 Table 32: Mutual relationship of mutations in different candidate genes 
  number of 
cases 
% of cases with mutation 
 exclusive ID3mut 32 51% 
 exclusive TCF3mut  2 3% 
 exclusive CCND3mut 4 6% 
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 Continue Table 32 
 exclusive ID3mut and 
TCF3mut 
3 5% 
 exclusive ID3mut and 
CCND3mut 
19 31% 
 exclusive TCF3mut and 
CCND3mut 
1 2% 
 ID3mut and TCF3mut and 
CCND3mut 
2 3% 
 total 63 100% 
 
 
Figure 24: Distribution of cases with certain combinations of ID3, TCF3 and CCND3 mutations. 
Each circles’ number represents the number of cases with mutations in the respective gene. 
Numbers in overlapping areas show summarize cases with mutations in multiple genes. 
This diagram was created using Venny (Oliveros, 2007). 
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Correlation with MYC rearrangement 
Results of Fluorescence-in-situ-Hybridization (FISH) for detection of MYC 
rearrangements were available for 78 cases of the studied cohort. Fifty-eight of 66 MYC 
rearrangement positive cases (88%) had at least one mutation in ID3 and/or TCF3 and/or 
CCND3. In contrast, within 12 MYC rearrangement negative patients only one harbored 
an ID3 mutation. 
Interestingly, the MYC FISH report of the case with ID3 mutation but no MYC 
rearrangement (case 68) states that 15% of the analyzed cells presented with an 
additional signal of MYC. In the report it was speculated that this observation might be 
the result of either a translocation with a proximal break-point of MYC or a result of a 
MYC duplication. As the MYC status of the respective case remained unclear, this case 
was not included in further MYC correlating analyses. 
 Table 33 shows the correlation between MYC rearrangement positive cases and cases 
with mutation in at least one of the three analyzed genes (p value < 0.0001). 
 
 Table 33: Correlation of mutation status with MYC rearrangement status 
  total ID3wt and TCF3wt 
and CCND3wt 
ID3mut and/or 
TCF3mut and/or 
CCND3mut 
p value (Fisher) 
 
 MYC 
rearrangement 
positive 
66 8 58  
 MYC 
rearrangement 
negative 
12 11 1  
 total 78 19 59 < 0.0001 
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Table 34: Overview of B-NHL patient sequencing results on ID3, TCF3 and CCND3 
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Reference diagnosis according to NHL-BFM study: Burkitt lymphoma (BL), Burkitt leukemia (B-AL), Diffuse large B-cell lymphoma (DLBCL), B-NHL 
unclassifiable (B-NHL DD), * no reference pathology review available;  ** no reference diagnosis available; MYC status: + MYC rearrangement positive, 
- MYC rearrangement negative, o MYC status unknown, +* MYC-Ig PCR positive; ID3, TCF3 (Exon 16) and CCND3 (Exon 5, coding region) mutation 
status: red block = mutated, black block = wildtype 
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3.2.3 Clinical characteristics and outcome according to ID3, 
TCF3 and CCND3 mutation status 
3.2.3.1 Correlation of ID3, TCF3 and CCND3 results with clinical characteristics 
Based on the high correlation between cases with mutation and concurrent MYC 
rearrangement clinical characteristics and outcome were analyzed within the group of 66 
MYC rearrangement positive B-NHL patients. 
However, there was no significant difference comparing the clinical features between 66 
MYC rearrangement positive B-NHL patients with and without ID3 mutation with respect 
to gender, age, stage of disease, BM involvement, CNS involvement and LDH levels. 
This was also the case for the comparison between TCF3mut and TCF3wt, as well as 
CCND3mut and CCND3wt cases. The clinical characteristics are summarized in Table 35. 
Regarding pEFS and pOS there were no significant differences between wildtype and 
mutated cases in the study cohort, as shown in the Kaplan-Meier plots for ID3 (Figure 
25, Figure 26), TCF3 (Figure 27, Figure 28) and CCND3 (Figure 29, Figure 30). 
 
Figure 25: Event-free survival (2 years) for 
ID3 mutated and non-mutated cases 
 
Figure 26: Overall survival (2 years) for ID3 
mutated and non-mutated cases 
  
 
Figure 27: Event-free survival (2 years) for 
TCF3 mutated and non-mutated cases 
 
Figure 28: Overall survival (2 years) for TCF3 
mutated and non-mutated cases 
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Figure 29: Event-free survival (2 years) for 
CCND3 mutated and non-mutated cases 
 
Figure 30: Overall survival (2 years) for 
CCND3 mutated and non-mutated cases 
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Table 35: Clinical characteristics of 66 MYC rearrangement positive patients with and without mutation in ID3, TCF3 and 
CCND3 
Characteristics ID3mut ID3wt p value TCF3mut TCF3wt p value CCND3mut CCND3wt p value 
Gender male 44 85% 13 93%  6 75% 51 88%  19 79% 38 90%  
 female 8 15% 1 7% 0.67 2 25% 7 12% 0.30 5 21% 4 10% 0.27 
Age < 10 31 60% 7 50%  7 88% 31 53%  16 67% 22 52%  
 10-14 14 27% 6 43%  1 12% 19 33%  5 21% 15 36%  
 > 14 7 7% 1 7% 0.48 0 0% 8 14% 0.18 3 12% 5 12% 0.44 
Stage of 
disease 
I 1 2% 2 14%  0 0% 3 6%  1 3% 2 5%  
disease II 8 17% 3 21%  4 50% 7 13%  5 21% 6 16%  
 III 25 52% 7 50%  2 25% 30 56%  8 34% 24 63%  
 IV 1 2% 1 7%  0 0% 2 4%  2 8% 0 0%  
 B-AL 13 27% 1 7% 0.18 2 25% 12 22% 0.12 8 34% 6 16% 0.09 
BM 
involvemen
t 
yes 13 25% 1 7% 0.27 2 25% 12 21% 0.67 8 33% 6 14% 0.12 
CNS 
involvemen
t 
yes 6 12% 1 7% 1.00 1 13% 5 7% 0.72 5 21% 2 5% 0.09 
LDH < 500 U/l 17 33% 9 64%  4 50% 22 39%  8 33% 18 43%  
 500-1000 
U/l 
11 21% 1 7%  2 25% 9 16%  5 21% 7 17%  
 > 1000 U/l 24 46% 4 29% 0.09 2 25% 26 46% 0.24 11 46% 17 40% 0.74 
Diagnosis BL 35 67% 11 79%  6 75% 40 69%  14 58% 32 14%  
 B-AL 13 25% 1 7%  2 25% 12 21%  8 33% 6 76%  
 DLBCL 3 6% 1 7%  0 0% 4 7%  1 4% 3 7%  
 B-NHL 
(DD) 
1 2% 1 7% 0.41 0 0% 2 3% 0.82 1 4% 1 2% 0.30 
Outcome pEFS (2y) 86 ± 5% 93 ± 7% 0.51 (LR) 88 ± 12% 88 ± 4% 0.92 
(LR) 
83 ± 8% 90 ± 5% 0.43 (LR) 
 pOS (2y) 88 ± 4% 93 ± 7% 0.64 (LR) 88 ± 12% 89 ± 4% 0.82 
(LR) 
87 ± 7% 90 ± 5% 0.74 (LR) 
Data refer to patients with successful investigation of the respective criteria. mut: mutated, wt: wildtype,, y: years, p value: probability value, BM: bone 
marrow, CNS: central nervous system, LDH: lactate dehydrogenase, U/l: Units per liter, pEFS: probability of event-free survival, pOS: probability of overall 
survival, LR: log-rank 
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3.2.3.2 Mutual relationship of mutations in the candidate genes and correlation 
with clinical characteristics 
To investigate differences between cases with certain combinations of ID3, TCF3 and 
CCND3 mutations, each combination that occurred in the mutual relationship analysis 
was evaluated separately with respect to clinical relevance.  
The genotypes were assessed for significant correlations with clinical relevance with 
respect to gender, age, stage of disease, CNS involvement, BM involvement, LDH levels, 
diagnosis, risk group and pEFS and survival. Results are summarized in Table 36. The 
complete data set of correlations between certain mutation patterns and clinical data is 
available in appendix 10.2. 
 Table 36: Correlation according to mutual relationship 
 Selection Number of 
cases 
Comparison of clinical characteristics 
according to mutated and wildtype status 
 ID3 52 no statistically significant results 
 TCF3 8 no statistically significant results  
 CCND3 24 no statistically significant results  
 ID3 exclusive 29 no statistically significant results  
 TCF3 exclusive 2 no statistically significant results  
 CCND3 exclusive 3 no statistically significant results  
 ID3 and/or TCF3 55 LDH, risk group 
 ID3 and/or CCND3 56 no statistically significant results  
 TCF3 and/or CCND3 29 gender, BM involvement, CNS 
involvement 
 ID3 and/or TCF3 and/or 
CCND3 
58 no statistically significant results  
 ID3 and TCF3 5 no statistically significant results  
 ID3 and CCND3 20 stage, BM involvement  
 TCF3 and CCND3 3 no statistically significant results  
 ID3 and TCF3 exclusive 3 gender 
 ID3 and CCND3 
exclusive 
18 stage, BM involvement, diagnosis 
 TCF3 and CCND3 
exclusive 
1 no statistically significant results  
 ID3 and TCF3 and 
CCND3 
2 no statistically significant results  
  
  
59 Results 
5
9
 
R
e
s
u
lts
 
Results of statistically significant differences are presented in the following: 
Selection: Cases with ID3 and/or TCF3 mutation 
 Frequency of ID3 and/or TCF3 mutations was higher in patients with LDH over 
500 U/l compared to patients with lower LDH levels (Table 37). 
 Frequency of ID3 and/or TCF3 mutations was higher in patients belonging to risk 
group R3 or R4 compared to patients with lower risk group (Table 38). 
 Table 37: Correlation of cases with ID3 and/or TCF3 mutation and LDH level 
 LDH level 
(U/l) 
total ID3wt and TCF3wt ID3mut and/or 
TCF3mut 
p value (Fisher) 
 
 LDH <500 26 8 18  
 LDH >=500 40 3 37  
 total 66 11 55 0.019 
 
 Table 38: Correlation of cases with ID3 and/or TCF3 mutation and risk group 
 Risk group total ID3wt and TCF3wt ID3mut and/or 
TCF3mut 
p value (Fisher) 
 
 R1 or R2 24 8 16  
 R3 or R4 40 3 37  
 total 64 11 53 0.014 
 
Selection: Cases with TCF3 and/or CCND3 mutation 
 Frequency of TCF3 and/or CCND3 mutations was higher in female patients 
compared to male patients (Table 39). 
 Frequency of TCF3 and/or CCND3 mutations was higher in patients with BM 
involvement compared to patients without BM involvement (Table 40). 
 Frequency of TCF3 and/or CCND3 mutations was higher in patients with CNS 
disease compared to patients without CNS disease (Table 41).  
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 Table 39: Correlation of cases with TCF3 and/or CCND3 mutation and 
gender 
 Gender total TCF3wt and 
CCND3wt 
TCF3mut and/or 
CCND3mut 
p value (Fisher) 
 
 male 57 35 22  
 female 9 2 7  
 total 66 38 28 0.036 
 
 Table 40: Correlation of cases with TCF3 and/or CCND3 mutation and BM 
involvement 
 BM 
involvement 
total TCF3wt and 
CCND3wt 
TCF3mut and/or 
CCND3mut 
p value (Fisher) 
 
 no 52 33 19  
 yes 14 4 10  
 total 66 37 29 0.032 
 
 Table 41: Correlation of cases with TCF3 and/or CCND3 mutation and CNS 
disease 
 CNS 
disease 
total TCF3wt and 
CCND3wt 
TCF3mut and/or 
CCND3mut 
p value (Fisher) 
 
 no 59 36 23  
 yes 7 1 6  
 total 66 37 29 0.038 
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Selection: Cases with exclusive combination of ID3 and TCF3 mutation 
 Frequency of exclusive combination of ID3 and TCF3 mutation was higher in 
female patients compared to male patients (Table 42). 
 Table 42: Correlation of cases with exclusive ID3 and TCF3 mutation and 
gender 
 Gender total Rest of the cohort ID3mut and 
TCF3mut only 
p value (Fisher) 
 
 male 57 56 1  
 female 9 7 2  
 total 63 63 3 0.047 
 
Selection: Cases with ID3 and CCND3 mutation 
 Frequency of cases with ID3 and CCND3 mutation was higher in patients with 
BM involvement compared to patients without BM involvement (Table 43). 
 Frequency of cases with ID3 and CCND3 mutation was higher in patients with 
stage B-AL compared to patients with other stages (Table 44). 
 Table 43: Correlation of cases with ID3 and CCND3 mutation and BM 
involvement 
 BM 
involvement 
total Rest of the cohort ID3mut and 
CCND3mut 
p value (Fisher) 
 
 no 52 40 12  
 yes 14 6 8  
 total 66 46 20 0.021 
 
 Table 44: Correlation of cases with ID3 and CCND3 mutation and stage 
 Stage total Rest of the cohort ID3mut and 
CCND3mut 
p value (Fisher) 
 
 I, II, III, IV 48 36 12  
 B-AL 14 6 8  
 total 62 42 20 0.048 
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Selection: Cases with exclusive combination of ID3 and CCND3 mutation 
 Frequency of exclusive combination of ID3 and CCND3 mutation was higher in 
patients with stage B-AL compared to patients with other stages (Table 45). 
 Frequency of exclusive combination of ID3 and CCND3 mutation was higher in 
patients with BM involvement compared to patients without BM involvement 
(Table 46). 
 Table 45: Correlation of cases with exclusive ID3 and CCND3 mutation and 
stage 
 Stage total Rest of the cohort ID3mut and 
CCND3mut only 
p value (Fisher) 
 
 I, II, III, IV 48 38 10  
 B-AL 14 6 8  
 total 62 43 18 0.017 
 
 Table 46: Correlation of exclusive ID3 and CCND3 mutation and BM 
involvement 
 BM 
involvement 
total Rest of the cohort ID3mut and 
CCND3mut only 
p value (Fisher) 
 
 no 52 42 10  
 yes 14 6 8  
 total 66 48 18 0.014 
 
 The occurrence of cases with mutation in two or more genes was higher in B-AL 
(9/14) when compared to BL (14/46) (Figure 31). This was also true when cases 
with ID3 and CCND3 mutations in combination were considered. These 
mutations were more often observed in B-AL compared to BL (BL 11/46, B-AL 
8/14; Fishers exact: p value < 0,045). 
Figure 31: Correlation between the number of affected genes and diagnosis  
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3.2.3.3 Number and location of ID3 mutations 
To investigate the impact of different ID3 mutations affecting specific functional regions 
of the ID3 protein on clinical characteristics, ID3 coding region was divided into four 
sections (Table 47). Sections were built upon the mutational distribution as presented in 
appendix 10.3, with section two and three representing mutations close to helix 1 and 
helix 2, respectively, and section one and four covering the up and downstream region 
of the functional domain. In cases with more complex alterations, like deletions, 
duplications and InDels, first affected amino acid residues were counted, respectively. 
 Table 47: ID3 mutation cluster analysis 
 Section Covered protein 
sequence (amino acid 
positions) 
Number of mutations in this section 
 1 1 to 40 3 
 2 40 to 59 28 
 3 60 to 80 36 
 4 81 and above 5 
 
There was no significant difference between mutations in different sections with respect 
to clinical characteristics and outcome (data not shown). 
Similar analysis was performed for the three most recurrently altered nucleotide 
positions, ID3 c.190, c.166 and c.241. There was no significant correlation for c.190 and 
c.166 cases.  
Cases with ID3 mutations that affected nucleotide position c.241 
 Frequency of ID3 mutations affecting nucleotide position c.241 was higher in 
patients with B-AL compared to BL stages I-IV. 
 Frequency of ID3 mutations affecting nucleotide position c.241 was higher in 
patients with bone marrow involvement compared to patients without bone 
marrow involvement (Table 49). 
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 Table 48: Correlation of ID3 mutations affecting c.241 and stage 
 Stage total Rest of the cohort c.241 ID3mut  p value (Fisher) 
 
 I, II, III, IV 48 47 1  
 B-AL 14 10 4  
 total 62 57 5 0.008 
 
 Table 49: Correlation of ID3 mutations affecting c.241 and BM involvement 
 BM 
involvement 
total Rest of the cohort c.241 ID3mut  p value (Fisher) 
 
 no 52 51 1  
 yes 14 10 4  
 total 66 61 5 0.006 
 
There was no difference between cases without, cases with one and cases with more 
than one mutation in ID3 regarding clinical relevance (data not shown). 
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3.3 ID3, TCF3 and CCND3 mutations in B-NHL 
patients who relapsed 
3.3.1 Patient characteristics 
To further investigate the prognostic role of ID3, TCF3 and CCND3 mutations, ten 
additional MYC rearrangement positive B-NHL patients were identified who suffered 
relapse. The initial sample not the relapse sample was analyzed. Cases were analyzed 
together with seven additional cases also suffering from relapse already included in the 
study cohort. 
3.3.2 Results of ID3, TCF3 and CCND3 sequencing 
In 17 relapsed/progressed MYC rearrangement positive B-NHL cases, occurrence of 
ID3, TCF3 and CCND3 mutations was 14/17, 1/17 and 6/17, respectively and therefore 
not significantly different from non-relapse cases with respect to frequency. 
Due to the sufficiently high number of ID3 mutations the pattern of ID3 mutations 
between cases with relapse/progress and cases with freedom of progression was 
investigated, to analyze for commonly affected mutation sites. However, there was no 
clear difference between the two groups, as visualized in Figure 32. 
Figure 32: Comparison of ID3 mutations between relapse and non-relapse cases. 
This figure refers to Figure 18. In addition, mutations found in relapsed cases are represented 
separately at the top of the figure. The respective case numbers are indicated. The blue dots 
delineate substitutions of relapsed cases. In the direct comparison there is no clear mapping of 
certain hotspot regions within relapse cases and no difference of mutational patterns compared 
to non-relapse cases.  
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3.4 ID3 sequencing in pB-ALL 
DNA samples from 96 pediatric pB-ALL patients were analyzed for ID3 mutations. Two 
out of 96 (2%) patients presented with genomic variants of ID3. Table 50 summarizes 
pB-ALL cases with genomic variants. 
pB-ALL-42 had one silent mutation in the coding sequence and duplication in the intronic 
region, likely without changes on protein level. Also pB-ALL-79 presented with a 
homozygous substitution in the intronic region. 
 Table 50: Genomic variants of ID3 in pB-ALL cases 
 pB-ALL-42 c.[240G>C(;)300+31_32dupACC] 
 pB-ALL-79 c.[301-49G>C] 
 
Unfortunately, corresponding germline material was not available for these cases to 
investigate the chance of germline mutations. However, remaining material from pB-ALL-
79 was available to perform MYC-FISH analysis showing an additional third MYC signal 
in the clones (Figure 33).  
 
 
Figure 33: MYC FiSH of pB-ALL case pB-ALL-79 
The image shows an interphase nucleus after hybridisation with fluorescent LSI MYC Dual Color 
Break Apart Rearrangement Probes (Abbott). Three MYC loci are represented by pairs of red and 
green labelled MYC specific probes (marked by arrows), indicating presence of an additional, 
third MYC locus (courtesy of Dr. A. Teigler-Schlegl, Oncogenetic Laboratory, University Gießen). 
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4 Discussion 
4.1 Patients, samples and methods 
Patients 
This study aimed to assess the frequency and relevance of ID3, TCF3 and CCND3 
mutations in pediatric B-NHL using a well-defined patient cohort that was uniformly 
diagnosed, treated and evaluated. Adequate material for tumor DNA extraction was 
available for 84 B-NHL patients representing the study cohort. In general the availability 
of tumor material for retrospective studies is limited and based on remaining samples 
after all diagnostic procedures. However, the number of samples analyzed in the study 
cohort corresponds approximately to the annual totals of pediatric B-NHL in Germany 
(GPOH Jahresbericht, 2013) and represents the so far largest cohort of pediatric B-NHL 
cases that has been analyzed and furthermore investigated for frequency and relevance 
of ID3, TCF3 and CCND3 mutations. 
All patients enrolled in this study were previously registered in the NHL-BFM study 
center. One of the aims of this infrastructure is to support and assure diagnosis and 
therapy on highest standard of care. In each case the final diagnosis was centrally 
assessed in the study center after careful review of histological, cytomorphological and 
genetic reports from associated reference institutions. The analyzed cohort of B-NHL 
patients featured the characteristics of the overall cohort and might therefore be seen as 
representative for pediatric B-NHL patients in Germany. 
Samples 
Tumor samples were available from the NHL-BFM biobank where the samples had been 
stored at minus 80 °C. DNA from pB-ALL cases was kindly provided from the ALL-BFM 
study center in Kiel (A. Möricke, M. Stanulla, M. Schrappe). The current study can serve 
as an informative example how the infrastructure of the clinical trials of the GPOH 
(Gesellschaft für Pädiatrische Onkologie und Hämatologie) supports research activities.  
For investigations of genomic alterations the tumor cell count in the samples used for 
DNA preparation is an important key point. In cases of very low tumor cell counts, 
mutations might be missed due to low representation of affected cells in the analyzed 
sample. For this reason the cytomorphological reviews of available liquid materials 
(effusion, ascites, bone marrow) were checked carefully and a sufficient percentage of 
blasts was confirmed before inclusion into this analysis. For the use of tumor tissue we 
checked the histology review report to confirm a sufficient tumor cell count. For a few 
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cases where no reference histology report was available, local pathology reports were 
used. 
Methods 
The experimental setup was tested and optimized before patient sample analysis. 
Capillary sequencing is a widely used and robust method for detection of genomic 
variants in respective DNA templates of interest. When samples showed disambiguates 
compared to the reference sequence they were analyzed again to confirm the finding. In 
all cases results were reproducible in validation experiments, giving evidence for robust 
functionality of the established experimental setup. 
In this study, tumor DNA from pediatric B-NHL samples was analyzed for mutations in 
different candidate genes. A certain limitation of the study approach lies in exclusive 
analysis of DNA extracted from the malignant cells missing the corresponding germline 
material. Therefore potential non-somatic mutations might be overseen by simply 
assuming somatic origin of the mutations found in tumor DNA. However, by the proof of 
somatic acquisition of mutations in ID3, TCF3 and CCND3 by the primary studies (Love 
et al., 2012; Richter et al., 2012; Schmitz et al., 2012) there is strong support to expect 
mutations of these genes to be acquired somatically. Also, in the previous investigation 
of ID3 variants in 209 cases of Sjögren’s syndrome, neither unknown variants nor 
germline mutations were reported (Sellam et al., 2008). In this context alterations 
detected in this study were generally considered to be somatic mutations. 
In the analyzed cohort of Richter et al. there were two cases presenting with focal loss 
of ID3 gene in the context of structural genomic alterations detected by single nucleotide 
polymorphism arrays (SNP-Array) (Richter et al., 2012). By the methods applied in the 
current study such genetical aberrations might not have been detected because PCR 
reactions only covered the genomic region of interest. Cases that presented with 
homozygous mutations might in fact be cases with complete loss of one allele and one 
remaining allele with mutation. And also for cases without mutations focal loss of ID3 
cannot be excluded. We performed detailed analyses to investigate whether biallelic ID3 
alterations differ from heterozygous alterations and could not support that hypothesis. 
Therefore the methodological risk to underestimate the rate of biallelic alterations seems 
acceptable assuming total disruption of ID3 gene function in either case. The uncertainty 
whether the rate of cases without any ID3 mutation might be overestimated and the 
clinical consequences from that risk must remain unsolved. 
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4.2 Frequency of ID3, TCF3 and CCND3 mutations in 
Burkitt lymphoma 
Recurrent genetic alterations in BL have recently been reported by three large scale 
next-generation-sequencing projects, in which all studies reported ID3 mutations to 
occur at high frequencies and almost exclusively in BL (Love et al., 2012; Richter et al., 
2012; Schmitz et al., 2012). While these studies were the first to describe genomic 
alterations of ID3 at all and equally evaluated these finding as hallmark in BL, there were 
striking differences regarding the ID3 mutation frequency in the studied cohorts, ranging 
between 34% (Love et al.), 58% (Schmitz et al.) and 68% (Richter et al.). This 
observation requires a more detailed insight into the studied cohorts, especially with 
respect to sample inclusion criteria and patient characteristics, to further evaluate 
potential causes for these inconsistencies. 
Schmitz and colleagues analyzed a collection of 78 sporadic BL samples obtained from 
pre-treatment patient biopsies and additional eleven EBV-negative BL cell lines. They 
performed Sanger sequencing of ID3, TCF3 exon 16 and CCND3 exon 5 and reported 
mutations in 58%, 11% and 38% of the cases, respectively. About one third of the 
analyzed samples were obtained from patients aged 18 or younger at diagnosis and the 
male:female ratio was 3:1. There were no information about assessment and 
confirmation of diagnosis (Schmitz et al., 2012). 
In the study of Richter et al. an extended collection of 100 MYC-rearrangement positive 
B cell lymphomas was analyzed by Sanger sequencing, showing 42 ID3 mutated cases. 
When using a previously established gene-expression classifier for selection of 
molecular BL (Hummel et al., 2006), 36 of 53 cases harbored ID3 mutations (68%). 
Regarding the molecular BL cases 65% of the analyzed samples were from patients 
aged 18 or younger at the time of diagnosis and the male:female ratio was 3:1. Histologic 
diagnosis was previously assessed in panel review. (Richter et al., 2012) 
In a third study, Love and colleagues reported ID3 mutations in 20 cases within a cohort 
of 59 MYC-rearrangement positive BL samples (34%), including 51 initial patient biopsies 
and eight cell lines. The analyzed cohort included 13 pediatric patients, however, 
information regarding age, gender and further characteristics was not available in the 
majority of cases. (Love et al., 2012)  
The current study presents the so far largest analysis of ID3, TCF3 and CCND3 mutation 
status in pediatric B-NHL and the analyzed cases were shown to feature representative 
characteristics for pediatric B-NHL in Germany (Table 25). ID3 mutations had an 
incidence of 77% in pediatric BL (including B-AL), most supporting the data from Richter 
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et al., but clearly diverging from the other two studies. In the following, selected aspects 
that contribute to these differences are discussed in more detail. 
1) Differences in the applied methods: While all primary studies used different next-
generation-sequencing technologies to analyze index cases of BL, validation of ID3 
mutations and mutation frequency assessment was performed in extended 
validation cohorts by Sanger sequencing. Primers used for PCR product 
amplification varied, but equivalently covered the coding region of exon 1 including 
the HLH coding region. Hence, differences in the applied methods are not sufficient 
to explain the variability of the reported ID3 mutation rates. 
2) Inclusion criteria of samples / diagnostic quality: The inclusion criteria for evaluation 
in the validation cohorts varied in between the presented studies (see above) and 
information on diagnostic quality was limited especially in the studies of Schmitz and 
Love. Attempts to determine the frequency of ID3 mutations in BL are further 
complicated by the diagnostic difficulty of BL. Despite enormous efforts to 
standardize histopathological differentiation of BL and DLBCL, this distinction is still 
vulnerable. Therefore careful histopathological review and description of the 
evaluated cases is necessary to allow the comparison of identified ID3 mutations 
rates. This is of exceptional importance in our study, as the rate of ID3 mutations in 
DLBCL is reported to be very low. Therefore a (un-)known mix of BL and DLBCL will 
not allow a robust estimate of the ID3 mutation rate in BL. Interestingly, Love et al. 
restricted their analyses to cases with proven MYC rearrangement. The rationale for 
that might be the attempt to enrich the analyzed cohort for BLs and to exclude 
DLBCLs, as the latter more infrequently harbor a MYC rearrangement. Despite 
these efforts, the rate of ID3 mutations in MYC positive lymphoma remains 
significantly different between the cohort reported by Love and colleagues and our 
cohort. Also not exactly known for the Love cohort, we expect that our cohort 
comprises much more pediatric B-NHL cases. Therefore the detected difference in 
the ID3 mutation rate might hint at a certain impact of patient age on the presence 
of absence of this mutation. In consequence, these data support the hypothesis of 
pathogenetic and biological differences between pediatric and adult BL. 
3) Biological differences according to patient characteristics: Primary studies included 
patients with varying distribution of age and there is strong evidence for differences 
in molecular presentation of BL between pediatric and adult patients. Trautmann et 
al. analyzed Ig repertoires and SHM status in molecularly classified BL and reported 
age biased differences in affected Ig heavy chain genes, with the mutation load 
being significantly higher in older BL patients (Trautmann et al., 2009). Furthermore, 
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McClure and colleagues studied morphologic and immunophenotypic features, as 
well as MYC and BCL2 status in Burkitt-like adult B-cell lymphoma and proposed a 
distinct biology for adult BL (McClure et al., 2005). 
These observations lead to the conclusion that ID3 mutation frequency might in fact be 
associated with more homogeneously presenting pediatric BL and occur less often in the 
more heterogeneous group of Burkitt-like adult B-cell lymphoma. 
The frequency of 13% TCF3 and 38% CCND3 mutations were consistent with the 
findings of Schmitz et al., who reported frequencies of 11% and 38% mutated cases, 
respectively (Schmitz et al., 2012). 
4.3 Functional background of ID3, TCF3 and CCND3 
mutations 
ID3 encodes for a small protein that functionally belongs to the family of dominant-
negative HLH transcription regulators and therefore lacks a basic functional site for DNA 
binding. The inhibitory effect on other HLH proteins is based on the formation of 
heterodimers via its HLH domain, causing subsequent interference on DNA binding 
capabilities to the partners transcription targets (Murre, 2005; Perk et al., 2005). In B-
cells isoform E47 of TCF3 is one of the partners interacting with ID3. Both, ID3 and TCF3 
are expressed at high levels in BL (Richter et al., 2012).  
The accumulation of ID3 mutations affecting the HLH domain was reported by the NGS 
studies. Furthermore, biallelic involvement and the occurrence of multiple mutations 
were indicated (Love et al., 2012; Richter et al., 2012; Schmitz et al., 2012). Several 
genomic mutants have been modeled and functionally analyzed in cell proliferation 
assays of ID3 mutant transfected BL cell lines and were shown to enhance G1 to S-
phase transition (Love et al., 2012; Schmitz et al., 2012). 
These findings are supported by the current study, showing that the majority of ID3 
mutations occurred in the crucial ID3 HLH-coding domain (Figure 18). Furthermore we 
found biallelic involvement in all tested cases with more than one mutation (Table 27). 
Besides large genomic deletions and insertions - partly resulting in new, early ending 
reading frames or complete loss of whole functional helices - more than two thirds of 
determined mutations were single nucleotide substitutions (Figure 20). Virtually all 
substitutions affected the HLH domain and resulted in either nonsense or missense 
mutations. The only three cases (case 5, case 56, case 78) harboring silent nucleotide 
changes had further concomitant non-silent mutations. In conclusion, all cases that were 
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affected by ID3 alterations had at least one mutation resulting in a change of ID3 amino-
acid sequence. 
As ID3 seems to be the most recurrently mutated gene in MYC rearrangement positive 
B-NHL and mutations have so far not been described in other malignancies, there is 
good evidence for a crucial role of ID3 in malignant transformation of these lymphomas. 
In this context the exceptional number and distribution of different mutations along the 
ID3 gene characterizes the fragility of ID3 protein structure with regard to successful 
function. 
The much lower frequency of TCF3 mutations promotes an inferior role in B-NHL 
compared to ID3 mutations. However, TCF3 mutations also affected its bHLH domain 
(Figure 21). Most mutations (N551K, E555Q, V557A, V557E, V559M) occurred in the 
coding region of the basic site, which is responsible for DNA binding on TCF3 targets. 
Other mutations affected the first helix (D561E) and the loop region (M575K). While the 
latter can easily be imagined to disrupt binding capabilities with ID3 and therefore might 
rescue TCF3 from ID3 inhibition, the effect of mutations affecting the DNA binding 
domain is less self-explanatory. Schmitz and colleagues showed that even mutations 
affecting the DNA binding site, like TCF3(V557E), resulted in failure of TCF3/ID3 
interaction while still being successful in binding to TCF3 targets. In general they reported 
isoform E47 to be higher expressed in TCF3 mutated cases, indicating a gain of function 
for TCF3 mutants (Schmitz et al., 2012). In this regard, ID3 and TCF3 mutations might 
both cause the same effect with respect to increased activation of TCF3 transcription 
targets. 
CCND3 was shown to be a direct target of transcriptional activation by TCF3 (Schmitz 
et al., 2012). Certain CCND3 mutant proteins have proliferative advantages by increased 
accumulation and activation of downstream targets in BL cell lines (Schmitz et al., 2012). 
The most common mutation in the current study was a frame-shift causing cytosine-
duplication at position c.811 (R271Pfs) that was also previously reported in other studies 
(Richter et al., 2012; Schmitz et al., 2012). Interestingly there were no cases with 
mutations affecting T283 in the cohort of Richter et al. and the current study, while 
Schmitz et al. reported recurrent mutations of this position in BL and DLBCL. This might 
indicate differences in the mutation pattern of CCND3 with respect to certain histology, 
as different rates of CCND3 mutations were reported for sporadic BL (38%), HIV-
associated BL (67%) and endemic BL (1.8%) (Schmitz et al., 2012). In conclusion these 
results for different groups of BL need further confirmation and evaluation in well-defined 
cohorts. 
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4.4 Clinical relevance of ID3, TCF3 and CCND3 
mutations in MYC rearrangement positive B-NHL 
Differential expression of ID proteins has previously been shown in a number of 
malignancies (Castanon et al., 2013; Kamalian et al., 2010; Kamalian et al., 2008; Li et 
al., 2010; Li et al., 2012; Sharma et al., 2012; Snyder et al., 2013; Strong et al., 2013) 
and lately evidence was provided for association between increased ID expression levels 
and more disseminated disease in prostate cancer, medulloblastoma and small lung cell 
cancer (Gupta et al., 2007; Maw et al., 2009; Phi et al., 2013). ID3 is also expressed at 
high levels in BL when compared to adult DLBCL (Richter et al., 2012), but due to its 
designated role as a tumor suppressor regarding TCF3 inhibition, its functional role in B-
NHL might be distinct from other malignancies. Mutations of ID3, TCF3 and CCND3 were 
shown to be potent drivers of cell proliferation and cell survival in mutant transfected cell 
lines (Love et al., 2012; Schmitz et al., 2012). 
First analysis of patient characteristics with respect to ID3 mutations was performed in 
the validation cohort of Richter et al. and tendencies towards lower age and favorable 
prognosis were stated for ID3 mutated cases (Richter et al., 2012). It is however difficult 
to compare pediatric and adult patients with respect to clinical characteristics and 
prognosis as treatment regimens are generally different and outcome is considerably 
worse in adult patients (Perkins and Friedberg, 2008). 
In the current study the clinical relevance of ID3, TCF3 and CCND3 mutations in pediatric 
B-NHL was investigated using the well-defined study cohort. As mutations in the three 
candidate genes were virtually exclusive in MYC rearranged cases 
(ID3mut±TCF3mut±CCND3mut: MYC rearranged 58/66 vs. MYC not rearranged 1/12; p 
value < 0.0001), relevance of the mutation status was tested within the group of 66 MYC 
rearrangement positive cases. While there was no obvious association between clinical 
characteristics and mutation status when investigating the candidate genes separately, 
certain mutational patterns in the pathway showed correlation with clinical criteria. 
Of particular note was the combination of ID3 and/or TCF3 mutations, which were 
discussed to be equivalent with respect to their function earlier. These cases were 
associated with higher LDH levels (ID3mut±TCF3mut: LDH <500 U/l 18/26 vs. LDH >=500 
U/l 37/40; p value 0.019), which is also reflected in an increased frequency of these 
cases in higher risk groups (ID3mut±TCF3mut: R1/R2 16/24 vs. R3/R4 37/40; p value 
0.014). Also, in patients with simultaneous ID3 and CCND3 mutations, the frequency of 
BM involvement and in consequence higher stage of disease was increased (exclusive 
ID3mut+CCND3mut: BM involvement yes 8/14 vs. no 10/52; p value 0.014).  These findings 
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may reflect advantages in proliferation and migration for respectively affected lymphoma 
cells, with the clinical correlate of advanced and more disseminated disease. However, 
biological interpretation of these results remains speculative for this time and must be 
evaluated in further functional analysis. 
Male patients are affected by BL up to five times more often compared to 
females (Burkhardt et al., 2005) and so far all experimental efforts to reveal the 
pathogenetic mechanism in this gender-specific shift failed. The number of female 
patients analyzed in this study was rather low in absolute count and therefore the 
interpretation of gender-specific analyses must be performed carefully. While TCF3 and 
CCND3 mutations did not associate to gender directly, the frequency of cases having 
either TCF3 mutation, CCND3 mutation or both were higher in female patients 
(TCF3mut±CCND3mut: female 7/9 vs. male 22/57; p value 0.036). This trend must be 
confirmed in a larger series of female patients before drawing any conclusions. The 
provoking hypothesis of such a study could be the assumption that BL in females is 
related to different pathogenic events as BL in males. 
Regarding ID3 mutation hotspots it is of notice that mutations affecting c.241, resulting 
in Q81* nonsense mutation on protein level, accumulated in cases with B-AL (ID3 
c.241mut: B-AL 4/14 vs. other diagnosis 1/52; p value 0.006) compared to stage I-IV 
disease. But after the inclusion of another non B-AL case in the extended cohort, the 
association turned under the level of statistical significance (data not shown). Further 
investigated ID3 hotspots at c.190 and c.166 did not show association to any clinical 
criteria. 
In our study cohort of only pediatric cases there was no association between ID3 
mutation status and age (Table 35). pEFS was 86±5% in  ID3mut cases compared to 
93±7% in ID3wt cases (log rank p value 0.5) and; rates for survival were ID3mut 88±4% 
vs. ID3wt 93±7%; (log rank p value 0.64). In certain sense, these findings represent a 
contrast to the data of Richter et al., where age-dependent ID3 mutation frequency and 
superior outcome for cases with ID3 mutations were reported. Again, one possible 
explanation is the more heterogeneous cohort analyzed by Richter et al. and the 
aforementioned general differences between BL in pediatric and adult patients. 
The detailed analyses of ID3 mutations, frequencies and patterns showed no significant 
difference comparing ID3 mutations in patients with or without relapse. This became 
more obvious after the addition of relapsed cases to the study cohort (Figure 32). None 
of the investigated genes seemed to have prognostic relevance with respect to pEFS 
and pOS (Table 35). These observations are quite comprehensible, as the high rate of 
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ID3 mutations did not offer much but the chance, that ID3 mutated cases are at a higher 
risk of relapse. The high number of ID3 mutations and recurrent involvement of its 
partners suggests an essential role of these alterations for BL lymphomagenesis, rather 
than a role for disease recurrence in a small subgroup of patients. 
4.5 ID3 mutations in pB-ALL and the role of MYC 
rearrangement 
Mature B cells have undergone Ig rearrangement and somatic hypermutation during B 
cell maturation. Initiation of malignant transformation caused by such mechanisms has 
been widely discussed and investigated in a number of studies: Goosens et al. provided 
evidence for the involvement of somatic hypermutation in the generation of chromosomal 
translocations including the Ig loci, like BL hallmark Ig/MYC (Goossens et al., 1998). 
However, Nepal and colleagues analyzed the contribution of somatic hypermutation-
mediating AID and Ig rearrangement-initiating RAGs to lymphomagenesis in MYC 
transgenic mice and did not find any direct effect between AID/RAG expression and 
subsequent lymphoma development (Nepal et al., 2008). In contrast, Pasqualluci et al. 
suggested somatic hypermutation to be the major contributor for aberrant translocations 
and mutations outside the intended locations in lymphomagenesis of DLBCL 
(Pasqualucci et al., 2001). Regarding ID3 mutations, Richter et al. showed enrichment 
of mutations in the RGYW-motif that is favorably affected by the AID (Richter et al., 
2012). 
While the actual roles of AID and RAG remain unclear with respect to malignant 
transformation and in particular generation of ID3 mutations, the analysis of pB-ALL 
cases in this study was thought to investigate the occurrence of ID3 mutations in a related 
malignancy, whose cells are pre-germinal centre cells and have not undergone somatic 
hypermutation. Assuming that the mutational mechanisms resulting in ID3 mutations are 
based on somatic hypermutation, any such mutations are unexpected in pB-ALL. And in 
fact, the vast majority of pB-ALL cases did not show any ID3 mutation and this finding 
therefore serves as next indication for a link between somatic hypermutation and ID3 
affection. However, in the cohort of 96 pB-ALL cases, two harbored genomic alterations 
in ID3. With regard to the effect on protein level, both cases presented with either silent 
or intronic alterations. Several assumptions and hypothesis might be derived from these 
findings: 
a) The two pB-ALL cases harboring ID3 variants showed genomic variants that are 
also present in germline. 
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b) The two cases might represent transitional malignancies between immature and 
mature B cell lymphoma. Cases of MYC rearrangement positive pB-ALL are 
reported at a small number (Greer et al., 2003; Hirzel et al., 2013; Meeker et al., 
2011). 
c) The underlying mechanism responsible for mutagenesis in B-NHL was also 
activated in these cases, but did not cause protein changing mutations and 
therefore remained phenotypically unobtrusive. 
d) Non-silent ID3 mutations require the environment of MYC activation, otherwise 
the ID3 mutated cells have no survival benefit and die. 
Interpretation of this finding is speculative and therefore demands further investigation 
of ID3 mutated pB-ALL cases. However, for one of the affected pB-ALL cases (pB-ALL-
79), it was possible to perform MYC-FISH analysis. While not observing any classical 
MYC rearrangement, the case presented with an additional signal of MYC in a lower 
number of cells. The third MYC signal indicates a third copy of the MYC locus and 
represents an interesting finding with respect to the concurrent finding of a genomic 
variant in ID3. Interestingly there was a similar case in the B-NHL cohort which had an 
ID3 mutation but was reported to have no MYC rearrangement but a third MYC signal 
copy (case 68). These findings raise the question whether additional MYC copies similar 
to MYC rearrangements support the occurrence of ID3 mutations. A future analysis of 
selected pB-ALL cases and other malignancies with additional MYC copies might shed 
light into mutual influence and dependency between ID3 mutations and MYC alterations. 
4.6 Consequence of ID3, TCF3 and CCND3 mutations 
in pediatric BL 
Burkitt lymphoma has been shown to be a homogenous malignancy in gene expression 
profiles, especially in comparison to the related group of DLBCL (Hummel et al., 2006; 
Lenze et al., 2011). Lately, results from whole-genome-sequencing of thirteen pediatric 
BL of the NHL-BFM group supported these observations on genomic level, showing a 
median of only 28 somatic mutations per tumor and a high frequency of recurrently 
affected genes even in the small number of twelve cases (Table 20, Table 21) (Rohde 
et al., 2013). 
In the current study, 88% of the analyzed MYC rearrangement positive cases had 
mutations in at least one of the three investigated candidate genes, representing 
affection of the ID3-TCF3-CCND3 pathway in the vast majority of pediatric BL cases 
(Figure 34).  
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Figure 34: ID3, TCF3, CCND3 pathway with frequency of respective mutations in MYC 
rearrangement positive B-NHL. 
Modified from Schmitz and Campo (Campo, 2012; Schmitz et al., 2012). 
 
In conclusion with the homogenous genomic landscape in pediatric BL and the so far 
exclusive finding of ID3 mutations in BL, these finding stress the evident relevance of 
this pathway especially in pediatric cases. The absence of clear associations to clinical 
characteristics and prognosis may even imply an essential function of pathway-
disruption for BL lymphomagenesis. Cases presenting without mutations might still be 
affected by focal loss of ID3 or mutations in other functional partners that are involved 
up- or downstream within the same pathway, likely in the BCR pathway, PI3K, CDK4/6 
and all their regulating genes. However, additional candidates will less likely present at 
similar high frequencies, as NGS studies so far should have covered most of the highly 
recurrent genomic events in BL. Investigation of more BL cases by NGS will be helpful 
to also cover mutations in genes that are distributed around the candidates analyzed in 
this study - that might be as relevant for lymphomagenesis - but only occur at much lower 
frequencies. 
These results demand a further functional evaluation of this pathway in many respects. 
Functional dependency on MYC alterations has to be investigated to better understand 
the causes for malignant transformation and uncover underlying mutational 
mechanisms. Furthermore, the overall high number of affected cases asks for 
therapeutic-targeting of this pathway. There is first promising evidence for successful 
application and efficacy of orally available CDK4/6 inhibitor PD 0332991, shown for 
tumor mass reduction in a BL-mouse model by Schmitz et al. (Schmitz et al., 2012). 
CDK4/6 inhibitors have recently also been shown to be effective in renal cell carcinoma 
cell lines and breast cancer cell line  (Finn et al., 2009; Logan et al., 2013) and are in 
preparation for clinical phase-I and II studies in breast cancer patients (U.S. National 
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Institutes of Health, 2013). Further investigation of this pathway will shed more light on 
molecular processes in BL and hopefully reveal more specific therapeutic options. 
4.7 Conclusion of the study 
In the current study, frequency and relevance of ID3, TCF3 and CCND3 mutations were 
studied in a uniformly diagnosed and treated cohort of pediatric B-NHL patients. The 
analyzed cohort had representative characteristics for pediatric B-NHL patients in 
Germany with respect to diagnosis, clinical features and outcome.  ID3 mutations were 
present in 77% of BL/B-AL cases, TCF3 and CCND3 showed mutations in 13% and 37% 
of the cases, respectively. As a result, we demonstrated that the occurrence of mutations 
in any of the analyzed genes was positively correlated with MYC rearrangement and 
88% of MYC rearrangement positive cases had at least one mutation in one of the 
investigated genes. Regarding the clinical characteristics in MYC rearrangement positive 
B-NHL, there was no relevant association of the ID3, TCF3 and CCND3 mutation status, 
with gender, age, stage of disease, BM involvement, CNS involvement, and LDH levels. 
Outcome was not associated with the mutation status. However, there was a tendency 
towards advanced stages and more disseminated disease in cases with certain 
concurrent mutations that demands further investigation of the respective patient groups. 
In the context of relatively homogeneous genomic alterations in pediatric Burkitt 
lymphoma, the high number of ID3 mutations found in this study of pediatric B-NHL 
patients suggests an essential role for this pathway with respect to lymphomagenesis 
and the phenotype of Burkitt lymphoma. 
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5 Summary (English/German) 
B-cell Non-Hodgkin Lymphoma (B-NHL) is the most common type of Non-Hodgkin 
Lymphoma in childhood and adolescent cancer patients. B-NHL can be further classified 
into subtypes, with Burkitt lymphoma (BL) being the most common entity in pediatric 
patients. Recently published large-scale next-generation sequencing studies unveiled 
sets of recurrently mutated genes in tumor cells of pediatric and adult B-NHL patients 
and introduced functionally related Inhibitor of DNA 3 (ID3), Transcription Factor 3 
(TCF3) and Cyclin D3 (CCND3) as potential drivers of BL lymphomagenesis. However, 
validation of these findings showed inconsistent mutation rates and assessment of 
clinical relevance was limited. 
In the present study frequency and relevance of mutations in ID3, TCF3 and CCND3 
were analyzed within a well-defined cohort of 84 uniformly diagnosed and treated 
pediatric B-NHL patients. Mutation frequency was 77% (ID3), 13% (TCF3) and 37% 
(CCND3) in BL (including Burkitt leukemia) and mutations remained almost exclusive for 
MYC rearrangement positive cases. ID3 mutations were detected in remarkably higher 
frequency than previously published. There was no clear association between mutation 
status and outcome, but certain concurrent mutations where enriched in more advanced 
stages of the disease. 
As a control group of a related malignancy, 96 samples from precursor B-cell leukemia 
(pB-ALL) patients were also analyzed for ID3 mutations. As expected, no mutations were 
found, but two cases showed genomic variants in ID3. Interestingly, for one of these 
cases it was possible to show a genetic alteration involving MYC, which is usually a key 
feature of BL.  
We conclude, that almost 90% of MYC rearrangement positive B-NHL harbored 
mutations in at least one of the investigated genes and therefore this study promotes the 
corresponding pathway to play an essential role in BL and especially in pediatric cases. 
 
  
  
80 Summary (English/German) 
8
0
 
S
u
m
m
a
ry
 (E
n
g
lis
h
/G
e
rm
a
n
) 
Zusammenfassung 
B-Zell Non-Hodgkin Lymphome (B-NHL) sind der häufigste Typ von Non-Hodgkin 
Lymphomen bei Kindern und Jugendlichen mit malignen Krebserkrankungen. B-NHL 
können weiter in Subtypen klassifiziert werden, in denen das Burkitt Lymphom (BL) die 
häufigste Entität bei Kindern und Jugendlichen darstellt. In der jüngsten Zeit haben 
Ganzgenomsequenzierungen von Tumorproben eine Liste von besonders häufig 
mutierten Genen in B-NHL von pädiatrischen und erwachsenen Patienten gezeigt. Unter 
anderem wurden die funktionell zusammenhängenden Kandidaten ID3, TCF3 und 
CCND3 als mögliche Antreiber der Lymphompathogenese bei BL beschrieben. 
Allerdings zeigten sich in verschiedenen Studien inkonsistente Mutationsfrequenzen und 
die Untersuchung der klinischen Bedeutung war limitiert. 
In dieser Studie wurden die Frequenz und Relevanz von Mutationen in den drei 
Kandidatengenen ID3, TCF3 und CCND3 in einer klar definierten Kohorte von 84 
einheitlich diagnostizierten und behandelten pädiatrischen Fällen mit B-NHL untersucht. 
In BL (inklusive Burkitt Leukämie) waren die Mutationsfrequenzen 77% (ID3), 13% 
(TCF3) und 37% (CCND3) und in Bezug auf die Gesamtkohorte kamen Mutationen in 
den untersuchten Kandidatengenen fast ausschließlich in Fällen mit gleichzeitiger MYC-
Translokation vor. Die Frequenz der ID3 Mutationen war unerwartet höher als bisher 
publiziert. Es zeigte sich kein klarer Zusammenhang zwischen dem Mutationsstatus und 
der Prognose. Es ergaben sich jedoch Hinweise für einen Zusammenhang von 
bestimmten Mutationskombinationen mit höheren Krankheitsstadien.  
In einer Kontrollgruppe von 96 pädiatrischen Fällen mit einer akuten Vorläufer-B-Zell 
lymphoblastischen Leukämie ließen sich keine ID3 Mutationen feststellen, sondern 
lediglich zwei Fälle mit nichtkodierenden Varianten. Interessanterweise gelang es, für 
einen dieser Fälle eine genetische Aberration des MYC-Gens nachzuweisen, dessen 
Translokation eigentlich die typische molekulare Veränderung für BL ist. 
Zusammenfassend lässt sich festhalten, dass nahezu 90% der untersuchten MYC-
rearrangierten pädiatrischen B-NHL eine Mutation in mindestens einem der drei 
untersuchten Kandidatengene aufwiesen und damit unterstreicht diese Arbeit die 
besondere Rolle der beschriebenen Gene, insbesondere in pädiatrischen Burkitt 
Lymphomen.
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6 List of abbreviations 
A/T Adenine/Thymine 
ACB Actibated B cell 
AID Activation-Induced cytidine Deaminase (protein) 
ALL-BFM Acute lymphoblastic leukemia - Berlin Frankfurt Münster study 
group 
ARF CDKN2A gene, alternate reading frame (gene) 
B-AL Burkitt Leukemia 
BAX bcl-2-like protein 4 (gene) 
BCL2 B-cell lymphoma 2  (gene) 
BCL6 B-cell lymphoma 6  (gene) 
B-CLL B-cell chronic lymphocytic leukemia 
BCR B cell receptor 
bHLH basic-Helix-loop-helix 
BL Burkitt Lymphoma 
BM bone marrow 
B-NHL B-cell Non-Hodgkin lymhoma 
B-NHL (DD) B-cell Non-Hodgkin lymphoma, unclassifiable between DLBCL 
and BL 
bp Base-pairs 
CCD Charge coupled device 
CCG Children's cancer group 
CCND3 G1/S-specific cylin-D3 (gene) 
CD Cluster of Differentiation 
CDK4/6 Cyclin-dependent kinase 4/6 (protein) 
CDKN2A Cyclin-dependent kinase inhibitor 2A (gene) 
c-MYC cellular - myelocytomatosis viral oncogene 
CNS Central nervous system 
CSR Class Swichting Recombination 
CXCL13 B lymphocyte chemoattractant (protein) 
CXCR5 Receptor 
Cyclin D3 G1/S-specific cyclin-D3 (protein) 
dATP Deoxyadenosine triphosphate 
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dbSNP Single Nucleotide Polymorphism Database 
ddH2O double distilled Water 
ddNTPs Dideoxynucleotides 
DDX3X ATP-depentdent RNA helicase DDX3X (gene) 
DKFZ Deutsches Krebsforschungszentrum 
DLBCL Diffuse Large B cell Lymphoma 
DLBCL-CB Diffuse large B-cell lymphoma - centroblastic variant 
DNA Deoxyribonucleic acid 
dNTP 2-Desoxyribonucleosid–5-triphosphate 
dNTPs Deoxyribonucleotides 
E.coli Escherichia coli 
e.g. exempli gratia 
E12 Isoform of TCF3 
E47 Isoform of TCF3 
EBF1 Early B cell Factor 1 (gene) 
EBV Epstein-Bar-Virus 
EDTA Ethelenediaminetetraacetic acid 
FAB French-American-British classification 
FBXO11 F-box only protein 11 (gene) 
FISH Fluorescence in situ hybridization 
g Gram 
G/C Guanine/Cytosine 
GC germinal centers 
GCB Germinal Center B cell 
GPOH  Gesellschaft für Pädiatrische Onkologie und Hämatologie 
H2O Water 
H-chain Heavy chain 
HIV Human immunodeficiency virus 
HLH Helix-loop-helix 
HSC Hematopoetic stemm cell 
ICGC International Cancer Genome Consortium 
ICGC-MMML-Seq International Cancer Genome Consortium - Molecular 
Mechanisms of Malignant Lymphoma by Sequencing 
ID1 Inhibitor of DNA 1 
  
83 List of abbreviations 
8
3
 
L
is
t o
f a
b
b
re
v
ia
tio
n
s
 
ID2 Inhibitor of DNA 2 
ID3 Inhibitor of DNA 3 
Ig Immunoglobulin 
Il Interleukin 
InDel Deletion followed by an Insertion 
IRF4 Interferon regulatory factor 4 (gene) 
kb Kilo base-pairs 
L-chain Light chain 
LDH Lacate dehydrogenase 
LR Log rank test 
M13 M13 primer 
MDM-2 Mouse double minute 2 homolog (gene) 
mut mutated 
MYC see c-MYC 
NCBI National Center for Biotechnology Information 
NGS Next-generation sequencing 
NHL Non-Hodgkin Lymphoma 
NHL-BFM Non-Hodgkin lymphoma - Berlin Frankfurt Münster study group 
OD Optical density 
p value probability value 
p21 p21/WAF1 (cyclin-dependent kinase inhibitor 1) (protein) 
p27 cyclin-dependent kinase inhibitor 1B (protein) 
P2RY8 P2Y purinoceptor 8 (gene) 
p53 protein 53 (protein) 
PAX5 Paired Box 5 (gene) 
pB-ALL Precursor B-cell acute lymphoblastic leukemia 
PBX1 Pre-B-cell leukemia transcription factor 1 (gene) 
PCR Polymerase chain reaction 
pEFS probability of event free survival 
PI3K Phosphatidylinositide 3-kinases 
PMBL Primary mediastinal B-cell lymphoma 
pOS probability of overall survival 
pre-B pre-B cell 
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pre-BCR pre-B cell receptor 
pro-B pro-B cell 
R Risk group 
Rag-1/-2 Recombination-activating gene 1/2 (genes) 
RB1 retinoblastoma 1 (gene) 
Rb1 Retinoblastoma protein 
RNA Ribonucleic acid 
SHM Somatic Hypermutation 
SMARCA4 ATP-dependent helicase SMARCA4 (gene) 
SNP Single Nucleotide Polymorphism 
SNP-Array Single Nucleotide Polymorphism-Array 
SNV Single Nucleotide Variation 
TAE Tris base, acetic acid, EDTA buffer 
TCF3 Transcription Factor 3 (gene) 
TdT Terminal deoxynucleotidyl transferas 
TP53 tumor protein 53 (gene) 
TP73 tumor protein 73 (gene) 
U Units 
UV Ultraviolett (light) 
V Volt 
VDJ Variable, Diversity, Joinging segments 
WHO  World Health Organization 
wt wildtype 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
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10.1 Overall sequencing results on B-NHL patients 
Overall ID3, TCF3 and CCND3 sequencing results on 84 B-NHL patients from the study cohort and 10 B-NHL patients from the extended cohort 
case diagnosis MYC 
rearr. 
DNA 
origin 
c.ID3 p.ID3 c.TCF3 p.TCF3 c.CCND3 p.CCND3 
1 BL yes ascites c.[198_199insCTAAG];[c.194G>A
] 
p.[V67fs*16];[S65N] wt wt c.[850C>T] p.[P284S] 
2 BL yes tissue wt wt c.[1724T>A] p.[M575K] c.[811dupC] p.[R271Pfs*53] 
3 BL yes tissue wt wt wt wt wt wt 
4 BL yes tissue wt wt wt wt wt wt 
5 BL yes tissue c.[141C>A(;)144C>T(;)166C>T] p.[C47*(;)P56S] wt wt c.[758_759dupA
G] 
p.[S254Rfs*50] 
6 DLBCL N/A tissue wt wt wt wt wt wt 
7 B-AL yes tissue c.[241C>T] p.[Q81*] wt wt c.[869T>G] p.[I290R] 
8 BL yes tissue c.[144C>G;243G>C];[236_243del
ACCTGCAG] 
p.[Y48*;Q81H];[D79GfsSPGRAS
PWTP*] 
wt wt wt wt 
9 BL yes tissue c.[180_190delAGGCACTCAGC] p.[R60Sfs*] wt wt c.[811dupC] p.[R271Pfs*53] 
10 BL yes pleura c.[153_164delGCGGGAACTGGT
];[256_266delGAGCCAGCCCC] 
p.[R52_V55del];[E86WfsTP*] wt wt wt wt 
11 BL yes ascites c.[144C>G];[300+1G>C] p.[Y48*];[V72_Q100del] wt wt wt wt 
12 BL yes tissue c.[236_247delACCTGCAGGTAG
] 
p.[L80PfsGRASPWTP*] c.[1675G>A] p.[V559M] c.[857_878delA
TGTCACAGCC
ATACACCTGT
A] 
p.[D286GfsPGE
ALWSGH*] 
13 BL yes ascites c.[142T>A] p.[Y48N] wt wt wt wt 
14 B-AL yes bm c.[241C>T] p.[Q81*] wt wt c.[778C>T] p.[Q260*] 
15 BL yes tissue c.[120delG(;)166C>T] p.[L40FfsWTT*(;)P56S] wt wt wt wt 
16 B-AL yes tissue c.[211C>T(;)241C>T] p.[Q71*(;)Q81*] wt wt wt wt 
17 DLBCL no tissue wt wt wt wt wt wt 
18 DLBCL N/A tissue wt wt wt wt wt wt 
19 B-NHL yes tissue wt wt wt wt c.[786_796dup] p.[A266Pfs*40] 
20 BL yes tissue wt wt wt wt wt wt 
21 DLBCL no tissue wt wt wt wt wt wt 
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case diagnosis MYC 
rearr. 
DNA 
origin 
c.ID3 p.ID3 c.TCF3 p.TCF3 c.CCND3 p.CCND3 
22 BL yes tissue wt wt wt wt wt wt 
23 BL yes tissue c.[236_251delinsC];[300+1G>C] p.[D79Gfs*?];[V72_Q100del] c.[1663G>C] p.[E555Q] wt wt 
24 BL yes tissue c.[190C>T] p.[L64F] wt wt c.[811dupC] p.[R271Pfs*53] 
25 BL yes tissue c.[143A>G] p.[Y48C] wt wt wt wt 
26 BL yes tissue c.[189delG] p.[Q63HfsLARWKSYSASSTTFS
TCR*] 
wt wt wt wt 
27 B-NHL yes tissue c.[152T>C(;)228C>G] p.[L51P(;)Y76*] wt wt wt wt 
28 DLBCL no tissue wt wt wt wt wt wt 
29 BL no tissue wt wt wt wt wt wt 
30 DLBCL yes tissue wt wt wt wt wt wt 
31 DLBCL yes ascites c.[166C>T(;)211C>T] p.[P56S(;)Q71*] wt wt c.[811dupC] p.[R271Pfs*53] 
32 BL yes tissue c.[190C>T] p.[L64F] c.[1653T>A] p.[N551K] wt wt 
33 BL yes tissue c.[190C>T] p.[L64F] c.[1675G>A] p.[V559M] c.[766_767delA
G] 
p.[R256Gfs*56] 
34 BL yes tissue wt wt wt wt wt wt 
35 BL yes tissue c.[167C>T];[181_209delGGCACT
CAGCTTAGCCAGGTGGAAATC
CT] 
p.[P56L];[G61WfsKSYSASSTTF
STCR*] 
wt wt wt wt 
36 BL yes pleura c.[167C>T(;)190C>T] p.[P56L(;)L64F] wt wt wt wt 
37 BL yes tissue c.[166_167delinsTT] p.[P56F] wt wt wt wt 
38 BL yes tissue wt wt wt wt c.[869T>G] p.[I290R] 
39 BL yes pleura c.[191_195delTTAGC] p.[L64PfsGGNPTARHRLHSRPA
GSPGRASPWTP*] 
wt wt wt wt 
40 B-AL yes bm c.[300+1G>T] p.[V72_Q100del] wt wt c.[782_792delC
CAGCTCCAGC
] 
p.[S263Afs*56] 
41 DLBCL no tissue wt wt wt wt wt wt 
42 B-NHL no tissue wt wt wt wt wt wt 
43 BL yes tissue c.[27_40delCTGCTACGAGGCG
G;202delG];[202delG];[27_40del
CTGCTACGAGGCGG] 
p.[C10VfsLPVGTQSGHRPGPRE
GPGS*;E68KfsSYSASSTTFSTC
R*];[E68KfsSYSASSTTFSTCR*];[
C10VfsLPVGTQSGHRPGPREG
PGS*] 
wt wt c.[811dupC] p.[R271Pfs*53] 
44 B-AL yes bm c.[137A>C(;)241C>T] p.[H45P(;)Q81*] wt wt c.[869T>A] p.[I290K] 
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case diagnosis MYC 
rearr. 
DNA 
origin 
c.ID3 p.ID3 c.TCF3 p.TCF3 c.CCND3 p.CCND3 
45 BL yes tissue c.[190C>T(;)233T>C] p.[L64F(;)L78P] wt wt wt wt 
46 DLBCL no tissue wt wt wt wt wt wt 
47 DLBCL yes tissue c.[241C>T] p.[Q81*] wt wt wt wt 
48 B-AL yes bm c.[181_270del] p.[G61_G90del] wt wt c.[850C>T] p.[P284S] 
49 BL yes tissue c.[116_delG] p.[S36Tfs*5] wt wt wt wt 
50 B-AL yes tissue c.[166C>T(;)209T>C] p.[P56F(;)L70P] wt wt c.[869T>G] p.[I290R] 
51 DLBCL no tissue wt wt wt wt wt wt 
52 B-AL yes bm wt wt c.[1670T>C] p.[V557A] wt wt 
53 BL yes tissue c.[134_140dupACCACTG];[209T
>C] 
p.[C48*];[L70P] wt wt wt wt 
54 BL yes pleura c.[214_243del;(214_243del)] p.[R72_Q81del;(R72_Q81del)] wt wt c.[811dupC] p.[R271Pfs*53] 
55 BL yes tissue c.[144C>G;(144C>G)] p.[Y48*;(Y48*)] wt wt c.[811dupC] p.[R271Pfs*53] 
56 DLBCL yes tissue c.[137A>C(;)161T>A(;)300+44T>
C(;)300+85C>T] 
p.[H45P(;)L54Q] wt wt wt wt 
57 BL N/A tissue c.[190C>T(;)230T>A] p.[L64F(;)I77N] wt wt c.[811dupC] p.[R271Pfs*53] 
58 DLBCL no tissue wt wt wt wt wt wt 
59 BL yes tissue c.[167C>G] p.[P56R] wt wt c.[850C>T] p.[P284S] 
60 DLBCL N/A tissue wt wt wt wt c.[864_873delA
GCCATACAC] 
p.[A289CfsSPG
EALWSGH*] 
61 BL yes pleura c.[141C>A(;)190C>T] p.[C47*(;)L64F] wt wt wt wt 
62 DLBCL no tissue wt wt wt wt wt wt 
63 BL yes ascites wt wt c.[1683T>G] p.[D561E] wt wt 
64 B-AL yes bm c.[167C>G] p.[P56R] wt wt c.[869T>G] p.[I290R] 
65 BL yes tissue wt wt wt wt wt wt 
66 B-AL yes bm c.[135C>G(;)166C>T(;)190C>T] p.[N45K(;)P56S(;)L64F] c.[1670T>A] p.[V557E] wt wt 
67 BL yes tissue c.[142T>G(;)166C>G(;)190C>G] p.[Y48D(;)P56A(;)L64V] wt wt wt wt 
68 B-NHL no pleura c.[20T>A(;)164T>A] p.[V7E(;)V55E] wt wt wt wt 
69 BL yes tissue c.[190C>T] p.[L64F] wt wt wt wt 
70 DLBCL N/A tissue c.[152_174dup(;)209T>G] p.[P59Cfs*32(;)L70R] wt wt wt wt 
71 BL yes ascites c.[122_140delTGGACGACATGA
ACCACTG_insC;(122_140delTG
p.[L41Pfs*73;(L41Pfs*73] wt wt c.[826C>T] p.[Q276*] 
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case diagnosis MYC 
rearr. 
DNA 
origin 
c.ID3 p.ID3 c.TCF3 p.TCF3 c.CCND3 p.CCND3 
GACGACATGAACCACTG_insC)
] 
72 BL yes ascites c.[243dupA] p.[V82Gfs*11] wt wt wt wt 
73 BL yes pleura c.[81delC];[247_248insTCTACAG
CGCGTCATCGACTACATTCTC
GACCTGCAGGTAG] 
p.[R28EfsGRARQLRSR*];[L84Yf
s*12] 
wt wt wt wt 
74 BL yes pleura wt wt wt wt c.[838C>T] p.[Q280*] 
75 BL yes tissue c.[166C>T] p.[P56S] wt wt wt wt 
76 B-AL yes bm c.[167_182dupCCGGAGTCCCG
AGAGG] 
p.[T62RfsSPERHSA*] wt wt c.[811dupC] p.[R271Pfs*53] 
77 BL yes tissue wt wt wt wt wt wt 
78 B-AL yes bm c.[189dedelG;193A>T];[190C>T] p.[Q63HfsFARWKSYSASSTTFS
TCR*];[L64F] 
wt wt wt wt 
79 B-AL yes bm c.[160C>G(;)164T>C] p.[L54V(;)V55A] wt wt wt wt 
80 B-NHL N/A tissue c.[160C>G];[165_166insG] p.[L54V];[P56AfsRSPERHSA*] wt wt wt wt 
81 B-AL yes bm c.[166C>G];[190C>G;206T>C;22
9A>G] 
p.[P56A];[L64V(;)I69T(;)I77V] wt wt wt wt 
82 BL no tissue wt wt wt wt wt wt 
83 BL yes tissue c.[166C>T(;)190C>T] p.[P56S(;)L64F] wt wt wt wt 
84 BL yes tissue c.[157delG(;)166C>G(;)209T>A] p.[P56A(;)E53NfsWYPESREALS
LARWKSYSASSTTFSTCR*(;)L7
0Q] 
wt wt wt wt 
 
extended cohort (cases 85-94) 
case 
ID 
diag. myc 
rearr. 
tumor 
origin 
ID3 (coding) ID3 (protein) TCF3 (coding) TCF3 (protein) CCND3 
(coding) 
CCND3 
(protein) 
85 BL yes ascites c.[190C>T(;)300+1G>C] p.[L64F(;)V72_Q100l] wt wt wt wt 
86 BL yes tissue wt wt wt wt wt wt 
87 BL yes tissue c.[166C>T(;)202lG] p.[P56S(;)E68KfsSYSASSTTFST
CR*] 
wt wt wt wt 
88 BL yes pleura wt wt wt wt wt wt 
89 BL yes ascites c.[167C>G;(167C>G)] p.[P56R;(P56R)] wt wt wt wt 
90 BL yes tissue c.[241C>T(;)300G>A(;)310C>T] p.[Q81*(;)Q100Q(;)L103F] c.[1675G>A] p.[V559M] wt wt 
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case diagnosis MYC 
rearr. 
DNA 
origin 
c.ID3 p.ID3 c.TCF3 p.TCF3 c.CCND3 p.CCND3 
91 BL yes tissue c.[93_dupG;(93_dupG)] p.[G31fsPGS*;(G31fsPGS*)] wt wt c.[856_866dup
GA] 
p.[D286Efs*18] 
92 B-NHL yes tissue c.[122_130lTGGACGACinsA;(12
2_130lTGGACGACinsA)] 
p.[L41Hfs*21;(L41Hfs*21)] wt wt wt wt 
93 B-AL yes bm c.[45C>A(;)202G>T] p.[C15*(;)E68*] wt wt wt wt 
94 B-AL yes tissue c.[190C>T(;)298C>T] p.[L64F(;)Q100*] wt wt c.[811dupC] p.[R271Pfs*53] 
 
wt: wildtype, bm: bone marrow, MYC rearr.: MYC-rearrangment, N/A: not available   
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10.2 Correlation between certain mutational patterns and clinical data 
Correlation between certain mutational patterns within 66 MYC rearrangement positive cases and clinical data. 
 ID3 ± CCND3 ID3 ± TCF3 TCF3 ± CCND3 ID3 ± TCF3 ± CCND3 
  mutated wildtype p value mutated wildtype p value mutated wildtype p value mutated wildtype p value 
Gender male 48 9  47 10  22 35  50 7  
 female 8 1 1.00 8 1 1.00 7 2 0.04 8 1 1.00 
Age < 10 34 4  34 4  21 17  36 2  
 10-14 15 5  14 6  5 15  15 5  
 > 14 7 1 0.34 7 1 0.16 3 5 0.81 7 1 0.09 
Stage of 
disease 
I 2   1 2  1 2  2 1  
II 10 1  9 2  7 4  10 1  
III 25 1  26 6  9 23  26 6  
IV 2 7  1 1  2 0  2 0  
B-AL 13 1 0.55 14 0 0.05 10 4 0.02 14 0 0.33 
BM 
involvement 
yes 13 1 0.68 14 0 0.10 10 4 0.03 14 0 0.19 
CNS 
involvement 
yes 7 0 0.58 6 1 1.00 6 1 0.04 7 0 0.58 
LDH level 
(U/l) 
< 500 20 6  18 8  10 16  20 6  
500-1000 11 1  11 1  6 6  11 1  
> 1000 25 3 0.34 26 2 0.05 13 15 0.75 27 1 0.08 
Diagnosis BL 38 8  37 9  17 29  39 7  
 B-AL 13 1  14 0  10 4  14 0  
 DLBCL 3 1  3 1  1 3  3 1  
 B-NHL (DD) 2 0 0.67 1 1 0.18 1 1 0.12 2 0 0.36 
Outcome  pEFS (2y) 87 ± 4% 90 ± 9% 0.8 (LR) 87 ± 5% 91 ± 9% 0.71 (LR) 83 ± 7% 92 ± 4% 0.27 (LR) 88 ± 4% 88 ±12% 0.99 (LR) 
 pOS (2y) 89 ± 4% 90 ± 9% 0.95 (LR) 89 ± 4% 91 ± 9% 0.86 (LR) 86 ± 7% 92 ± 4% 0.47 (LR) 90 ± 4% 88 ±12% 0.84 (LR) 
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 ID3 exclusive TCF3 exclusive CCND3 exclusive ID3 + TCF3 
  mutated wildtype p value mutated wildtype p value mutated wildtype p value mutated wildtype p value 
Gender male 28 29  2 55  3 54  3 54  
 female 1 8 0.07 0 9 1.00 0 9 1.00 2 7 0.13 
Age < 10 15 23  2 36  2 36  4 34  
 10-14 10 10  0 20  1 19  1 19  
 > 14 4 4 0.7 0 8 0.47 0 8 0.8 0 8 0.52 
Stage of 
disease 
I 1 2  0 3  1 2  0 3  
II 3 8  0 11  1 10  3 8  
III 17 15  1 31  0 32  1 31  
IV 0 2  0 2  1 1  0 2  
B-AL 4 10 0.27 1 13 0.87 0 14 0.002 1 13 0.14 
BM 
involvement 
yes 4 10 0.24 1 13 0.38 0 14 1.00 1 13 11.00 
CNS 
involvement 
yes 1 6 0.12 0 7 1 1 6 0.29 1 6 0.44 
LDH level 
(U/l) 
< 500 10 16  0 26  2 24  3 23  
500-1000 5 7  0 12  0 12  2 10  
> 1000 14 14 0.68 2 26 0.25 1 27 0.54 0 28 0.12 
Diagnosis BL 22 24  1 45  2 44  4 42  
 B-AL 4 10  1 13  0 14  1 13  
 DLBCL 2 2  0 4  0 4  0 4  
 B-NHL (DD) 1 1 0.63 0 2 0.78 1 1 0.16 0 2 0.9 
Outcome  pEFS (2y) 93 ± 5% 84 ± 6 % 0.27 (LR) no 
events 
87 ± 4% 0.61 (LR) no 
events 
87 ± 4% 0.52 (LR) 80 ± 
18% 
88 ± 4% 0.50 (LR) 
 pOS (2y) 93 ± 5% 86 ± 6% 0.4 (LR) no 
events 
89 ± 4% 0.63 (LR) no 
events 
89 ± 4% 0.55 (LR) 80 ± 
18% 
90 ± 4% 0.42 (LR) 
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 ID3 + CCND3 TCF3 + CCND3 ID3 + TCF3 + CCND3 ID3 + TCF3 exclusive 
  mutated wildtype p value mutated wildtype p value mutated wildtype p value mutated wildtype p value 
Gender male 15 42  3 54  2 55  1 56  
 female 5 4 0.11 0 9 1.00 0 9 1.00 2 7 0.05 
Age < 10 13 25  2 36  1 37  3 35  
 10-14 4 16  1 19  1 19  0 20  
 > 14 3 5 0.48 0 8 0.8 0 8 0.77 0 8 0.31 
Stage of 
disease 
I 0 3  0 3  0 3  0 3  
II 3 8  2 9  1 10  2 9  
III 8 24  1 31  1 31  0 32  
IV 1 1  0 2  0 2  0 2  
B-AL 8 6 0.16 0 14 0.25 0 14 0.76 1 13 0.18 
BM 
involvement 
yes 8 6 0.02 0 14 1.00 0 14 1.00 1 13 0.52 
CNS 
involvement 
yes 4 3 0.19 0 7 1.00 0 7 1.00 1 6 0.29 
LDH level 
(U/l) 
< 500 5 21  2 24  1 25  2 24  
500-1000 5 7  1 11  1 11  1 11  
> 1000 10 18 0.27 0 28 0.31 0 28 0.35 0 28 0.31 
Diagnosis BL 11 35  3 43  2 44  2 44  
 B-AL 8 6  0 14  0 14  1 13  
 DLBCL 1 3  0 4  0 4  0 4  
 B-NHL (DD) 0 2 0.09 0 2 0.71 0 2 0.82 0 2 0.92 
Outcome  pEFS (2y) 80 ± 9% 91 ± 4% 0.22 (LR) no 
events 
87 ± 4% 0.52 (LR) no 
events 
87 ± 4% 0.61 (LR) 67 ± 
27% 
89 ± 4% 0.16 (LR) 
 pOS (2y) 84 ± 8% 91 ± 4% 0.48 (LR) no 
events 
89 ± 4% 0.55 (LR) no 
events 
89 ± 4% 0.63 (LR) 67 ± 
27% 
90 ± 4% 0.11 (LR) 
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 ID3 + CCND3 exclusive TCF3 + CCND3 exclusive 
  mutated wildtype p value mutated wildtype p value 
Gender male 13 44  1 56  
 female 5 4 0.05 0 9 1.00 
Age < 10 12 26  1 37  
 10-14 3 17  0 20  
 > 14 3 5 0.31 0 8 0.69 
Stage of 
disease 
I 0 3  0 3  
II 2 9  1 10  
III 7 25  0 32  
IV 1 1  0 2  
B-AL 8 6 0.77 0 14 0.32 
BM 
involvement 
yes 8 6 0.01 0 14 1.00 
CNS 
involvement 
yes 4 3 0.08 0 7 1.00 
LDH level 
(U/l) 
< 500 4 22  1 25  
500-1000 4 8  0 12  
> 1000 10 18 0.21 0 28 0.46 
Diagnosis BL 9 37  1 45  
 B-AL 8 6  0 13  
 DLBCL 1 3  0 4  
 B-NHL (DD) 0 2 0.04 0 2 0.93 
Outcome  pEFS (2y) 77 ± 
10% 
92 ± 4% 0.14 (LR) no 
events 
88 ± 4% 0.72 (LR) 
 pOS (2y) 83 ± 9% 92 ± 4% 0.35 (LR) no 
events 
89 ± 4% 0.74 (LR) 
 
All data refer to patients with successful investigation of the respective criteria. mut: mutated, wt: wildtype,, y: years, p value: probability value, BM: bone marrow, 
CNS: central nervous system, LDH: lactate dehydrogenase, U/l: Units per liter, pEFS: probability of event-free survival, pOS: probability of overall survival, LR: 
log-rank 
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10.3 ID3 gene segmented into sections 
The ID3 gene plot was segmented to four sections that were separately analyzed for relevance with respect to clinical characteristics. 
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115 Appendix 
10.4 List of SNP identifiers 
This list presents identifiers of Single nucleotide polymorphisms (SNPs) according to the dbSNP 
database (NCBI dbSNP database, 2013) that were taken into account in sequence analysis and  
data interpretation.  
 
 dbSNP identifier (ID3) 
 rs201368186 
 rs81216731 
 rs184371695 
 rs146711026 
 rs41268121 
 rs150987910 
 rs11574 
 rs202157091 
 rs139428797 
 rs201697476 
 rs201313484 
 rs147380623 
 rs26739388 
 rs147934602 
 rs74062742 
 rs201701997 
 rs190449947 
 rs11542315 
 rs146163818 
 rs199661785 
 rs142720912 
 rs61749352 
 rs138633497 
 rs201168120 
 rs146156581 
 rs2067053 
 rs200199499 
 rs34462407 
 rs142466418 
 rs146830460 
 rs140027264 
 rs148870313 
 rs148996867 
 rs138679775 
 rs11542319 
 rs180772482 
 rs141280661 
 dbSNP identifier (ID3) 
 rs147689987 
 rs11542317 
 rs201488898 
 rs81216730 
 
 dbSNP identifier (TCF3) 
 rs187316941 
 rs200962332 
 rs201939465 
 rs200433738 
 rs182233043 
 
 dbSNP identifier (CCND3) 
 rs1051130 
 rs201507759 
 rs200046302 
 rs147958536 
 rs202197675 
 rs142862109 
 rs3218101 
 rs3218103 
 rs3218102 
 rs33966734 
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Bonn BR, Zimmermann M, Damm-Welk C, Russel RB, Borkhardt A, Eils R, Hoell JI, 
Szczepanowski M, Oschlies I, Klapper W, Burkhardt B, Siebert R) 
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Given at the 12th International Conference on Malignant Lymphoma, 19-22 June 2013, Lugano, 
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S. Eberth, M. Hummel, W. Klapper, J. O. Korbel, M. Loeffler, P. Rosenstiel, A. Rosenwald, L. 
Truemper, A. Reiter, R. Siebert and B. Burkhardt) 
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12 Declaration (in German) 
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